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ABSTRACT 
 
The study investigate if adherence counselling improves adherence to antiretrovirals. The aim 
of the study is to improve adherence to antiretrovirals and reduce morbidity and mortality rate 
due to HIV/AIDS. The study used One Group Post Test -only design. The  participants in the 
study were measured on adherence to antiretrovirals  after they have received three seessions 
of adherence counselling. 
 
The objectives of the study was to : 
To explore the adherence behaviour of patient on antiretrovirals 
To deterrmine the adherence rate of patient on antiretrovvirals 
To determine the impact of adherence on adherence counselling 
To explore relationship between different demographic variables and adherence 
To explore relationship between different adherence measures 
 
The study brings  to the front the HIV/AIDS picture.The crippling of the parts of the society 
by HIV/AIDS. The prevalence of HIV and the impacts HIV has on, nations, individuals 
,household and industries are brought into perspective.  
 
The study goes back to the origin of HV/AIDS and further  tackles issues related to 
HIV/AIDS and adherence, which are the anatomy, physiology, basic knowledge and 
discription of HIV/AIDS.The study tackles antiretrovirals, their classes, regimen side effect 
and important consideration while on antiretrovirals. The   effectiveness of the antiretroviral  
therapy  in  reducing  morbidity and mortality is discussed as well as the efforts  by different 
countries globally in the roll out of antiretrovirals to fight the pandemic. 
 
The study explores the challenges to adherence to antiretrovirals and possible intervention. In 
this study adherence, adherence to antiretrovirals, predictors of adherence, barriers to 
adherence, adherence strategies and measures of adherence are  explored.Assesment and 
intervention durring adherence counselling are discussed. The study results supported our 
hypothesis, that  adherence counselling improves adherence to antiretrovirals. 
 
 
 
 
OPSOMMING  
 
Die studie ondersoek of getrouheidsberading wel getrouheid tot antiretrovirale behandeling 
bevorder. Die doel van die studie is om te getrouheid tot antiretrovirale behandeling te 
bevorder en sieklikheid en mortaliteit koers wat aan MIV/Vigs verwant is te verminder. Die 
studie gebruik een groep na-toets -alleen ontwerp. Die deelnemers in die studie was gemeet 
op getrouheid tot antiretrovirale behandeling na hulle drie sessies berading ontvang het.  
 
Die doelwitte van die studie was:  
 
Om getrouheid van die pasiënt op antiretrovirale behandeling te bepaal  
Om die koers van getrouheid van die pasiënt op antiretrovirale behandeling te bepaal   
Om die impak van gebrouheid op getrouheidsberading te bepaal   
Om die verhouding tussend verskillende demografiese veranderlikes en getrouheid te bepaal  
Om die verhouding tussend verskillende getrouheidsmetings te bepaal  
 
Die studie bring die MIV/Vigs situasie na vore. Die voorkoms van MIV en die impak wat dit 
op nasies, individue, huishoudings en nywerhede het, is in perspektief gestel. 
 
Die studie gaan terug tot die oorsprong van MIV/Vigs en kyk na MIV/Vigs verwante 
kwessies soos anatomie, fisiologie, basiese kennis en beskrywing van MIV/Vigs.  Die studie 
kyk na antiretrovirale behandeling, hul klasse en newe-effekte. Die effektiwiteit van die 
antiretrovirale behandelling word bespreek asook die pogings deur verskillend lande 
wêreldwyd in die uit rol van antiretrovirale behandeling om die pandemi te beveg.   
 
Die studie ondersoek die uitdagings van getrouheid tot antiretrovirale behandeling en 
moontlike ingryping. Getrouheid tot antiretrovirale behandeling, voorspellers, hindernisse, 
strategieë en metings van getrouheid word in die studie bespreek. Die resultate van die studie 
ondersteun ons hipotese dat getrouheidsberading wel getrouheid tot antiretrovirale 
behandeling verbeter. 
 
 
 
 
 
 
DEFINITION OF TERMS  AND ACRONYMS 
ADCC-Antibody Dependant Cellular Cytotoxicity 
AIDS-Acquired Immune Deficiency Syndrome 
ARV’s-Antiretrovirals  
BSL 3-Biosafety Level 3 
CARES-China AIDS Response 
CBO-Community Based Organization 
CCMT-Comprehensive Plan for HIV and AIDS Care,Management  and Treatment 
CDC- Centre for Disease Control 
DNA-Deoxy Ribonuleic Acid 
DOH-Department of Health 
DREAM-Drug Resource Enhancement against AIDS and  Malnutrition. 
 EIA-Enzyme Immmuno Assay 
FBO-Faith Based Organization  
FDA-Food and Drug Adminisrtation  
HAART-Highly Active Antiretroviral Therapy  
HEART-Help Enhance  Adherence  to Antiretroviral Therapy 
HIV-Human Immune Deficiency Virus  
IFA-Immunofluorescence Assay  
MC- Male Circumcission 
NGO-Non –Governmental Organization 
PCR-Polymerase Chain Reaction 
PCP-Pneumocystis Carinii Pneumonia 
PEP-Post Exposure Prophylaxis  
PLWA-People Living With HIV/AIDS  
PMTCT-Prevention of Mother to Child Transmission of HIV/AIDS.  
RNA-Ribonucleic Acid 
SAAVI-South African AIDS Vaccine Initiatives 
SAHIVSOC-South African HIV Society of Clinicians  
STI-Sexually Transmitted Infection 
UNAIDS-Joined United Nation Programme on AIDS 
VCT-Voluntary Counselling and Testing  
WHO-World Health Organization 
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CHAPTER 1 
 
1.1 INTRODUCTION TO THE STUDY 
HIV/AIDS pandemic is a challenge Worldwide  to individuals, families, industries and  
nations. Worldwide 2.0  millions lost their lives due to HIV/AIDS in 2007 and 33 million are 
living with HIV/AIDS. Mortality and morbidity due HIV/AIDS, left the world in distress. 
The people are grieving for their loved ones and at the same time, dealing with the burden of 
HIV/AIDS. 
 
Countries worldwide are making urge effort to combact the pandemic. The effort is focused 
on prevention, treatment, care and support, human rights, monitoring and evaluation and 
more research to impact the epemic (UNAIDS, 2008). 
 
We believe countries effort in education in order to reduce discrimination are succesfull, as 
globally individuals tends to accept those who are living with HIV/AIDS. However there are 
still people who discriminate against those who are living with HIV/AIDS. It is very 
discouraging to know that in this day in time there are still people who are involved with such 
acts. HIV affects also of us, if it does not infect us. People living with HIV/AIDS are humans 
,they need support, motivation and love like any other person. 
 
In  2003 November the South African  Cabinet approved the national operational plan for the 
comprehensive HIV/AIDS, Care, Management and Treatment (CCMT). Therefore CCMT 
were accredited to issue antiretrovirals (DOH, 2007). 
 
Antiretrovirals are the drugs used to supress the viral replication in order to prolong the lives 
of those who are living with HIV/AIDS. Antiretrovirals are life long treatment they have side 
effects and toxicity. They are to be taken as they are prescribed. This is called adherence, 
which also includes changes in with life styles that are contrary with adherence to 
medication.In order for the treatment to be effective, thus suppresing  viral replication, 
adherence rate has to be ≥ 95%. However there are other classes of antiretrovirals which 
achieve viral suppression with adherence of lower than 95%. 
 
 
 
Studies in the United state report evarage adherence among patient on antiretrovirals to be 
70%. Non – adherence to antiretroviral put tha patient at arisk of developing drug resistance. 
Drug resistance is likely to be followed by morbidity and mortality (Machtinger, 2008). 
 
1.2 STATEMENT OF THE PROBLEM 
Adherence requires medication to be taken as prescribed, the keeping of appointment, the 
changing of lifestyles and behaviour which are not appropriate to adherence. Adherence to 
antiretrivirals prolong life of those who are on antiretrovirals. It requires  an adherence of ≥ 
95% for the full suppression of the virus (Machtinger, 2008). 
 
Non adherence to antiretrovirals may results with the development of drug resistance  The 
resistance strain can be transmitted to the next person. The drug resistance to antiretrovirals 
reduces the treatment  options of those who are affected. 
 
Adherence to antiretrovirals is a challenge to people living with HIV/AIDS. There are many 
patient reported to be defaaulting to antiretrovirals in the public sectors. A study in 
Johannesburg reported that one in every six  patient who where on antiretrovirals defaulted 
treatment over a 15 months period (UNAIDS, 2008). 
 
1.3 THE SIGNIFICANCE OF THE STUDY 
According to Brink ( 1999) the study is  significant if  its  finding  will be beneficial, increase 
the knowledge and help in the improvement of policies. The study will increase knowledge of 
health care professional on adherence to antiretrovirals and issues related to adherence. It will 
further assist in developing and improving policies on adherence and adherence counselling. 
 
 1.4 RESEARCH QUESTION 
What is the effect of adherence counselling on adherence to antiretrovirals? 
 
1.5 RESEARCH OBJECTIVES 
To explore the adherence behaviour of patient on antiretrovirals 
To deterrmine the adherence rate of people on antiretrovvirals 
To determine the impact of adherence on adherence counselling 
To explore relation ship between different demographic variables and adherence 
To explore relationship between different adherence measures  
 
 
1.6 OPERATIONA L DEFINATION 
Adherence Counselling- This is the discusion with the clients on information regarding, the 
basic knowledge of HIV/AIDS, antiretrovirals drug literacy, adherence strategies, dietary 
information, coping strategies and the importance of following doctor’s prescribtion. 
Antiretrovirals-this are the drugs that inhibit the viral replication.They antagonize the 
virus.They controll the HIV, by supressing viral load and improves the immune system. 
 
1.7 FORMULATION OF THE HYPOTHESIS 
According to Burns (2001) hypothesis is the statement of the expected relationship or 
relationships between variables. Hypothesis predicts the outcome of the study. In our study 
the hypothesis is Adherence counseling increases, adherence to antiretrovirals. 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 2 
 
2. RESEARCH METHODS 
 
2.1 RESEARCH DESIGNS 
One group post Test –Only Design is used. The single group of participants willbe measured 
on the dependant after treatment condition. In our case the one group of participants from the 
Pretoria West Hospital Comprehensive, Care, Management and Treatment of HIV willbe 
measured onthe dependant variable which is adherence counselling (Christensen, 2002). 
 
2.2 SAMPLING DESIGN 
Random sampling technique was used in selecting the subject, to participate in the study. 
Systematic Interval Sampling will be used. This means the selecting of the at equal 
intervals,for  an example every 3rd, 5th, 6th element. The number of the population was 
divided by  the sample size.to get the sampling inteval.In cases the sampling interval is two, 
every 2nd person within the total population for that day participated in the study 
(Brink,1999). 
 
Data was collected at Pretoria West Hospital, in Gauteng Province South Africa. The 
Hospital is situated at the Western part of Pretoria in area called Phillip Nel. Its Catchment 
Area is Danville, Lotus Garden, Daspoort, Karen Park, Proclamation Hill and Laudium. It 
provides maternity, family planning, Laboratory Services, curative and HIV/AIDS services. 
The HIV/AIDS services include Prevention of Mother to Child Transmission of HIV/AIDS. 
(PMTCT), TB/HIV collaboration, Voluntary Counselling and Testing and Comprehensive, 
Care, Treatment, Management of HIV/AIDS (CCMT).  
 
The participants in the study will be both males and females with ages ranging from 15 years 
and upwards, who received three sessions of adherence counselling prior initiation with 
antiretroviral and have been on treatment for ≥6 months.  
 
2.3 DATA COLLECTION INSTRUMENT 
The data was collected using Morisky Scale, Visual Analogue Scale, Pill Count, Last three 
days methods, and the evaluation of CD4 count and viral load results to assess adherence to 
antiretroviral. 
 
 
2.4 ETHICS 
Anonymity, Confidentiality and Privacy was ensured .Access to information about the 
participants was controlled and was not revealed to anyone outside the research group. 
Informed consent was revealed from the participants before commencing with the study. 
Pretoria West Hospital gave the permission for conducting the study (Christensen, 2002). 
 
2.5 PILOT STUDY 
Pilot study is a small scale study which is collected before the actual study, a small number of 
participants from the same population which of the study in used in pilot study. The problems 
are identified early and dealt with. The pilot study also assess the feasibility of the study 
(Brink, 1999). The pilot study was conducted at Pretoria West Hospital  with eight patient, 
who received three sessions of adherence counselling prior to initiation with Antiretrovirals. 
Problems were identified and dealt with, hence the data collection with the actual study was 
smooth and easy. 
 
 2.6 DATA ANALYSIS 
Data was analysed using SAS, which is Statistical Analytic Software . 
 
 
  
 
 
CHAPTER 3 
 
3. LITERATURE REVIEW 
 
3.1 THE PREVALENCE OF HIV/AIDS 
Globally, there is an estimation of 33 million living with HIV. The annual number of new 
infections has decreased from 3.0 million in 2001 to 2.7 miliion in 2007. The annual number 
of HIV infection is declining  in countries as Asia, Latin America and Sub- Saharan Africa.In 
2007 2.0 million people worldwide died of HIV, compared with 1.7 million in 2001 
(UNAIDS, 2008). 
 
Sub –Saharan Africa in 2007 had a new infection rate 1,9 million in 2007. Sub –Saharan 
Africa is the home of 67% of peopleliving with HIV/AIDS.In the same year adult prevalence 
has exceddded 15% in seven Sub- Saharan African countries and above 5% in other seven 
countries.However the pandemic in Sub –Saharan Africa seems to have stabilized. Data 
collected from South Afrian countries as Zimbaabwe indicate that the HIV prevalence among 
pregnat women attending antiretroviral clinic fell from  26% in 2002 to 18% in 2006 and a 
decline of 25 % in 2001 to 18% in 2006 was noticed in Botswana. It must be noticed that data 
from pregnant women gives an indication of epidemiological trends (UNAIDS, 2008). South 
Africa in 2007 had 35% HIV infection and 38 % of HIV death.Nearly six million South 
Africans are living with HIV/AIDS (The star, 2008). 
 
 370000 children under the age of 15 became infected with HIV in the year 2007.The nomber 
of the children living with HIV under the age of 15 increased from 1.6 million in 2001 to 2.0 
million in 2007. 90 % of these who are infected with HIV leave in Sub – Saharan Africa. 270 
000 of children infected with HIV died in 2007.HIV is the reason for the death of over one 
third of the childern under the age of five. Globally the percentage of people living with HIV 
remains at 67% (UNAIDS, 2008). 
 
3.2 THE IMPACT OF HIV/AIDS 
HIV/AIDS impacts are the effects the pandemic is having on the society. According to 
Barnett and Whiteside (2002) impacts lead societies to take paths that it would have not 
taken; without the impacts of microbes originating in Europe which wiped 95% of the 
 
 
population, America would have a different population composition ,culture,economy,and 
political system. 
 
HIV/AIDS impacts demography, economy, individuals,household  and the other sectors of 
the government as the education, social and health. In measuring impacts countries conducts 
census and survey, to measure key demographic indicators. This and household indicators are 
used to calculate  other indicators as total fertility rate, growth, dependancy, age, structure, 
life expectancy,  infant, child and martenal mortality rate (Whiteside, 2002). 
 
The Impacts of HIV/AIDS on the Demography 
Demoraphy deals with the population dynamics. It looks at the number,growth and the 
structure of the population and the indicators which are birth, death, fertility, life expectancy, 
infant and child mortality rate (Barnett et al., 2002). 
 
The Impact of HIV/AIDS on Mortality Rate 
HIV/AIDS increases mortality rate worlwide. A meta –analysis study discovered that 
mortality in Africa has risen in the 1990’s. It was found out that death rate among adults aged 
15-44 in Abidjan, Cote d’Ivore was due to HIV, same applied to death in Tanzania among 
adult aged 15-59. A study done in Uganda reported that death was more prevalent among 
HIV positive individuals, than their peers who were HIV negative. 
 
 The Impacts  of HIV/AIDS on Life Expectancy 
According to Barnett et al., (2002). life expectancy is the describtion of the level of mortality 
measured in years, with specification of the population and time. 
According to  the United Nations Development Programme, human development reports and 
bereau of the census,  it was estimated that life expectancy  in South Africa was  63.2 in 1993  
as compared to 35.5 in 2010 and the life expectancy in Kenya was estimated to be 55.5 in 
1993 as compared to 44.3 in 2010 (Whiteside 2002). According to DOH (2004) mortality rate 
in 1990 suggested that the 15 year old had a 29% chance of dying before the age of 60, but 
the mortality rate in 2006 suggest that a 15 year old had a 56% chance of dying before the 
age 60.  
 
 
 
 
 
The Impacts  of HIV/AIDS on Infants and Child Mortality Rate 
According to the South African National Strategic Plan, the under 5 mortality has increased 
from 65 death per1000 births in 1990  to 75 death per 1000 in2006. Mother To Child 
Transmission of HIV increases infant morality rate. Rakai Cohort study found that mortality 
was 225 per 1000 for children born to HIV positive mothers and 97.7 for chidren born to HIV 
negative mothers. Many infant will leave beyond their first birthday, but few will survive 
beyond their fifth (Whiteside, 2002). 
 
The impacts of HIV/AIDS on infant and child mortality is contrary, to the internatinal 
development goals set by the Develpmental Assistance Comitte of the OECD to reduce infant 
and chid mortality by two thirds by 2015, thus Sub-sahara Africa need to move from 1990 
rate of 101 per thousand  to 33 in 2015 (Whiteside, 2002). 
 
The Impacts of HIV/AIDS on Fertility 
Number of birth will absolutely be affected if women die ,before reaching the end of their  
childbearing age. In  Africa one third of lifetime birth occur to women over the age of 30 
years. HIV reduces fertility. In Masaka it was found out that fertility rates were 20-30% less 
among HIV infected women (Whiteside, 2002). 
 
The  Impacts of  HIV/AIDS on Population Size and Growing  
It is envisaged that HIV will reduce the number  of population, thus the population will be 
smaller that it would have been  without AIDS.Variuos studies estimated that by the year 
2003, Botswana, Zimbabwe and South Africa will experience a negative population growth a 
down to -0.1 to -0.3 from 1.1 to 2.3 in the absence of AIDS (Whiteside, 2002). 
 
The  Impacts of  HIV/AIDS on Dependancy Ratio and Orphans 
This is the number of dependants, which is the children under the  age of 15 and adults above 
the age of 64 per 100 adults aged 15-64 by years of productive age. The dependancy ratio is 
adversely affected by HIV/AIDS, because AIDS increases mortality among young adults and 
children (Whiteside, 2002). 
 
 
 
 
 
 
The Impacts of HIV/AIDS on Economy  
HIV reduces income and increases expenditure.In cases were most workers especially skilled 
workers,are sick ,absent from work or are dead .The economy becomes affected.The output 
of firms and impact measures as Gross domestic Products are affected (Whiteside, 2002). 
HIV can slowly reduce economic rate and is likely to reduce ecomomic growth from 0.5% to 
1.5% over 10-20 years in high prevalence areas (UNAIDS, 2008). 
 
HIV/AIDS  results in high morbidity and mortality rate. The work force is also affected. The 
situation reduces production. The sick workers will often absent themselves from the work 
due to poor health. The production of the company is affected severly, especially if the absent 
employee is the skilled worker who is responsible for the most of the corporation’s product. 
The company can also be affected by the death of the skilled workers, as the death may 
indicate they have to hire and train other workers. The result is the loss of profit. 
 
It is envisaged that the economic growth is much slower with AIDS than it is without AIDS 
and that over a 5 years period the economy could be up to 25 % than it would have been 
without AIDS. The low life expectancy reduces growth by 1.3%. In 1999 RSSC sugar 
(Swaziland ) estimates death attributable to HIV/AIDS as 9.41/1000. In one of the companies 
in South Africa in the year 1999 the impacts of HIV/AIDS on salaries was 1.1 %of the 
operating profit, 3.4% of pretax profits and 4.6 of after tax profits. Again HIV could reduce 
the number of potential customers. Many markets which are depending  on population size 
could be more vulnerable (Whiteside, 2002). 
 
The Impacts of HIV/AIDS on Health 
The quality  of health service is  affected.Hospitals as a results of HIV/AIDS admit many 
patient. At times they are unable to manage the number of the client they have admitted. 
Once the patient are stable, they are discharged, in order to accomodate critically ill  patients. 
Health proffesionals are overworked, due to the large numbers of patient.  In that case they 
provide poor quality of service, due to exhaustion. They absent themselves from work in 
order to rest. These results with the shortage of staff to provide the quality of care. 
 
Acoording to UNAIDS (2008) the pandemic results in more expenses to the government.In 
Zambia due the delivery capacity was reduced by 6.2%, labour cost increased by nearly 10%.  
 
 
It is estimated  that by 2010 the Botswana government will have to spent 7-18% of the 
budget. More will be on  health ,poverty alliviation and employment(Whiteside, 2002). 
 
The Impacts HIV/AIDS on the Individual and Household. 
Poverty, lack of education , reduced income and broken families may occur as a results of 
poverty. Due to the death of the parents children may end up heading the family or we may 
have a broken family as children may stay with different relatives. The sick bread winner, 
may loss his/her job, or his/her salary spent on medical expenses. The family then leave in 
poverty due to reduced income or no income at all. Parents with no income may fail to pay 
the educational expenses of their children or children may not concentrate at school due to 
bad circumstances at home. 
 
Acording to UNAIDS (2008) the pandemic has impacts on household. In India the pandemic 
consume 82% of the poorest annual income and 20% income of the wealthiest. In Botswana 
share of the household has increased to below the poverty line by 6%.HIV /AIDS will slow 
the annual rate of poverty reduction by  60%, in Cambodia, 38% in Thailand and 23% in 
India between 2003 and 2010 or12. 
 
There are other impacts on HIV, on the educational and social sector. For example with high 
numbers of teachers being infected with HIV/AIDS, children, education will be affected as 
teachers will be sick and absenting themselves from work or dying due to HIV/AIDS. The 
icreased number of orphans will affect the social welfare.  
 
3.3 WHAT IS HIV /AIDS 
HIV is the abbreviation of Human Immunodeficienccy Syndrome. HIV causes AIDS. AIDS 
stand for the Acquired Immuno deficiency Syndrome. The virus has different stages of which 
AIDS is the last stage. During this stage the clients is infected with the opportunistic 
infection. The Immune system cells which are the CD 4 count are not sufficient to protect the 
body against this opportunistic infections. 
 
3.4 THE PROGRESSION  OF HIV TO AIDS 
The progression from HIV to AIDS differs with individuals. However there are other factors 
as the availability of treatment, pregnancy, stress, poor nutrition and poverty, which affect the 
progression from HIV to AIDS. 
 
 
In cases where there is no intervention  with treatment progression to HIV/AIDS tends to be 
faster than it would have  been  with treatment. According to Gert (2008 ) without 
intervention the individual dies after 7-10 years of infection. 
 
Evian (2003) report that there are rapid progressors, slow progressors and non- progressors to 
HIV/AIDS. It may take 5-7 years for a rapid progress to develop AIDS. Some rapid 
progressors  develop AIDS 3-4 after infection with HIV/AIDS. The slow progressors may be 
well for a long time with no disease and immune deficiency or little of those. They may 
remain well for 10-15 years or more.The non progressor, which usually constitute 5% of 
those HIV infected people, may never progress to AIDS or any immune deficiency. 
 
3.5 THE MODE OF THE SPREAD OF HIV 
 
The Sexual Transmission of HIV/AIDS 
HIV  can be transmitted through sexual intercourse, ( unsafe sex), with the infected person.  
Anal sex and oral sex also transmit HIV/AIDS. The other factors that increases  the  sexual 
transmission of HIV, are sexual transmitted diseases, promuscuity and having sexual 
intercourse during menstruation. 
 
The Blood Transmission of HIV/AIDS. 
The bloood transmission of HIV/AIDS can happen during exposure to the infected blood. For 
example during blood transfusion with the infected blood, during delivery of the baby where 
the infected mother’s blood can be in conduct with the baby, during accidents, in 
occupational setting as the health setting, where the health care worker can sustain sharp 
instrument injury from an infected patient and during  injection drug use. 
 
Mother to Child  Transmission of HIV/AIDS  
According to Hubley(2002) HIV can be transmitted from mother to Child during pregnacy, at 
birth, and during breastfeeding. The risk of mother to child   transmission of HIV in children 
who are not breastfed is 15-25%, and in children who are breastfed is 25-45%. It is envisaged 
that HIV is likely to be transmitted during labour when there is prolonged time between the 
rapture of the membrane and the delivery of the baby.  
 
 
According to Policy Project (2001) heterosexual transmission of HIV/AIDS account for 88% 
of HIV transmission, Mother to Child transmission account for 10%, while blood transfusion 
account for 2% of HIV infection.  
 
Other fluids as the saliva have a lower concentration of HIV. There is a less risk of the 
transmission of HIV, if an HIV positive person is kissed. Any lesions in the mouth may 
increase the likely hood of HIV transmission (Hubley, 2002). There are report of people who 
are not contracting HIV, even after they are  exposed to the risk of contracting HIV/AIDS as,  
unsafe sex. According to Avert (2006), HIV uses its two proteins gp120 and gp 41 to attach 
to the CD 4 and beta chemokines receptors (CCR5 /CXCR4). People who lacks this beta 
chemokine receptor as a results of genetic mutation or due to blockage by chemical 
messengers (natural chemokines) may not be infected by HIV or may progress to AIDS 
slowly if they are infected.  
 
3.6 FACTORS FACILITATING THE TRANSMISSION OF HIV/AIDS. 
Lack of HIV/AIDS Education –Lack of HIV education is responsible for the increase in the 
number of HIV/AIDS infection. The lack of information on the basic knowledge of 
HIV/AIDS as the mode of transmission, risky behaviour and the prevention can results with 
individuals engaging with risky behaviours without even knowing it. Education is appropriate 
at the family level, school level and the community level. 
 
According to UNAIDS (2008), the HIV/AIDS basic knowledge is still below the global goal 
of ensuring comprehensive HIV knowledge in 95% of youg people by 2010 ( as far as 
declaration commitment on HIV/AIDS, 2001, Survey data from 64 countries states that 
comprehensive knowledge of HIV/AIDS is 40% in males and 38% in females. The number 
of people having sex before the age  of 15 is around 12% in males and around 11% in 
females.  
 
Perception of Risk- It was found out that even though many peple have knowledge on HIV, 
the pandemic continue to spread.In a study conducted in  Malawi, the participants who knows 
about HIV/AIDS reported their percived risk of contracting HIV/AIDS as small or non 
existing (Policy Project, 2001).  
 
 
Multiple Sexual Partners –  Multiple sexual partners fuel the spread of HIV/AIDS.According 
to Zambia Sexual Behaviour Survey as cited in Policy Project (2001) 39% of sexually active 
men and 17% of sexually active women had a non regular partner within the past 12 months 
Sexually Transmitted Diases -According to Policy Project (2001) the prevalence of sexually 
transmitted disease is fuelling the spread of HIV/AIDS. Sexually Transmitted Infections  
remain untreated, especially  in areas of weak health System. 
 
 Commercial Sex Work-commercial sex work also increases the spread of HIV/AIDS. Again 
sex workers may find themselves in situations were they are forced to usafe sex and at the 
same time they engage in sexual activities with many Partners. Low level of Cicumciission-
Uncircumcised men are at risk of contracting HIV than the circumsised men.According to the 
study done in Zambia only 7% of men were circumcised (Policy Project, 2001).  
 
Population of humaritarian concern-The population of humaritarian concern refers, to the 
displaced population/people.These are people affected by conflicts, disaster and other 
emergencies.The risk of HIV in this population is due to mobility, infrastructure destruction, 
sexual violence, rape, breakage of social norms and other factors associated with 
displacement (UNAIDS, 2008).  
 
Incarceration-Incarceration is considered as a risk factor for HIV/AIDS infection. Rape, 
homosexuality, unsafe sex, intravenous drug use and risk of blood exposure due to violence 
are activities happening within the correctional facilities (DOH, 2007). Violence –Rape is 
among the drivers of the pandemic in South Africa. Rape cases in  South Africa, continue 
increase, rather than declinine. According to the study by interpol, International Police 
Agency, South Africa lead the world with rape cases and  every 17 seconds the women was 
raped. 30% of adolescents reported that their first sexual experience was forced. 16% of men 
believe women who were raped enjoyed the experience and asked for it. In 2003, 52 425 
cases were reported in South Africa, while in 2006, 55000 rape cases were reported and 
450 000 estimated cases of rape were not reported (Rape Survivor Journey, 2009). 
 
Migrant Labour System -Moving from one area to the other or one country to the other 
increases the spread of HIV. The individuals who are away from their families and partners 
for a long time as a results of migration ,tends to have other  sexual partners were they are 
staying. Policy Project (2001) report that some major  projects may require men to live their 
 
 
families for an extended period, which lead men to engage in sexual activities with  people  
other than their partners.  
 
According to the DOH (2007) HIV is  prevalent is among people aged 15-49 in urban 
informal settlement. Studies report the rate of HIV to be  25.8% in urban informal settlement 
as compared to 13.9% in urban formal settlement. Settement Patterns- Urbanization and 
transition from traditional to modern culture give rise to newpatterns of sexual behaviour 
(Policy Project, 2001). Injecting Drug use- Injecting drug use increases the exposure.There is 
an expasion of 5% t0 50% in one year among injection drug users (UNAIDS, 2008). Lack of 
women empowerment-the disempoerement of women is responsible for the high transmission 
of HIV/AIDS. Lack of empowerement results with women being unemployeed. Women 
tends to rely on men for survival. Women end up being involved with exchange sex, 
intergenerational sex, agree to unsafe sex to make money. The situation is even worse in 
marriages  women find it difficult to negotiate safe sex due to lack of empowerement. 
 
In Botswana and Swaziland the women who lacks sufficient food are 70% less likely to 
perceive personal control in sexual relationships, 50% are are likely to engage in 
intergenerational relationships, 80% are more likely to engage in survival sex and 70% are 
more likely to engage in unsafe sex than those who arerceiving adequate nutrition (UNAIDS, 
2008). 
 
According to whiteside (2002) Women account for 50% of people living with HIV/AIDS. 
Cultural Practices. Women are expected to obey their husband traditionally. Reasoning with a 
man in many cultures shows disrespect. Women find themselves in situation where they 
cannot insist on safe sex , even if they know about their partners’s infedilility. According to 
Policy Project (2001) there is no relationship between polygamy and HIV transmission. 
Observers belief polygamy is contributing to the spread of HI/AIDS. Polygamy can be risky 
in cases were one partnner is unfaithful. These will lead  to the spread of HIV to the whole 
cycle of polygamy. Traditional healers in their healing processes often use sharps and 
instument  on different people without sterilizing themwhich they contnue to use on the next 
person without strerilising them (DOH, 2007).  Lack of Political Commitment-Politicians has 
a great influence on citizens. The more they debate about a particular issue, people may take 
it seriuos. The spread of HIV can decline with political commitment (Gert, 2008). 
 
 
 
3.7 THE PREVENTION OF HIV/AIDS  
The transmission of HIV can be prevented through the abstinance from sex. The avoidance of 
multiple partners, thus being faithfull to one partner and the practice of safe sex through the 
use of condoms. The Information, Education and Communication campaigns (IEC) are 
effective in the batlle against HIV. Information can be provided through HIV/AIDS 
education in schools, health education in clinic and the campaigns in communities and the 
workplace. The distribution of the pamplets  on HIV, the use of the media,the comminity 
mobilization can help in the reduction of HIV campaigns. The education must includes the 
the basic knowledge of HIV/AIDS, behavoiur change, perception of risk, stigma and 
discrimination and HIV prevetion. 
 
Partnership with the Community Based Organization (CBO), Faith Based Organization 
(FBO), Traditional healers and People Living with HIV/AIDS (PLWA) may play a urge role 
in the prevention of HIV/AIDS transmission. The FBO and the CBO may assist in reffering 
the patient  for the health treatment.If knowledge is given to te traditional healers on 
HIV/AIDS, more especially on the risk of transmission of HIV/AIDS, the incidence of blood 
transmission will be reduced as they will always sterilize their equipments, to reduce the HIV 
transmission. 
 
Community Mobilization involves the training of peer educators, Voluntery Couselling and 
Testing counsellors, Life skill educators within the communoties ti disseminate information 
on HIV/AIDS. According to Policy Project (2001), the screening of blood and donors for 
safety, is an effective strategy in reducing the transmission of HIV/AIDS .The rolling out of 
antretrovirals in preventing and treating HV/AIDS is another means of spreading the 
transmission of HIV. The management of opportunistic infections, as well as Tuberculosis 
and HIV collaboration. 
 
More studies on vaccines and antiretrovirals will be of assistance in the battle against 
HIV/AIDS. Circumcission reduces the risk of HIV/AIDS infection. It  is envisaged that men 
who are are circumcissed, has a lower risk of contracting HIV/AIDS than uncercumcissed 
men. The roll out of male circumcission will decrease the spread of HIV in men and 
indirectly in women.It was found out that, in countries were circumcission is more practiced, 
the HIV prevalence was low than those countries which practice less circumsion.The state 
 
 
public health institution should offer circumcission, with the equipment which are safe and 
meet infection control requirements (Bertran, 2007). 
 
According to Policy Projects (2001), individuals who has undergone Voluntary Counselling 
and Testing (VCT) change their sexual behaviour. Studies proves that VCT is effective as a 
preventive strategy. Programmes and Policies to address HIV/AIDS transmission to be 
initiated and developed. The programmes and policies must focus on addressing violence, 
discrimination, human rights, women empowerement, migration issues, and poverty and 
protecting the vulnarable. UNAIDS (2008) report that countries need to put in place evidence 
–informed policies and programmes indealing with HIV/AIDS. 
 
In empowering women, information, education and skills can be provided to women. 
UNAIDS (2008) reported that the implementation of scaled –up measures to increase women 
independency is required, in order to mitigates HIV impacts on women. 90% of women who 
participated in microfinanace initiatives, reported  that  their lives has changed to the best. 
The strengthening of the health system, the provision of the basic infrastructure and the 
provion of quality health services has an impact in the prevention of HIV/AIDS.  
 
The prevention strategies above should reach all the population, including those at risk as the, 
injecting drug users, the youth, population of humaritarian concern, men who have sex with 
men, commercial sex workers, prisoners and e.t.c.  
 
Combination of all the intervention is effective in reducing HIV/AIDS rather than the 
implementation of one intervention. The monitoring and the evaluation of the cos 
effectiveness of the preventive strategies is very important in the prevention of HIV/AIDS 
(Policy Project, 2001). 
 
Countries  Efforts in the Prevention of HIV/AIDS 
Countries developed  the strategic plans in managing and treating HIV/AIDS. 69% of 
countries report having a national strategy which is translated into operational plan with 
goals,targets and costing. Half of the countries strategedy meets UNAIDS quality assurance 
(UNAIDS, 2007). South African National AIDS Council  in 2007, under the leadership of the 
Deputy President  Phumzile Mlambo Ngcuka, mandated the Department of Health to develop 
 
 
HIV/AIDS  national strategic plan 2007-2011, refererring to the 2000-2005 HIV/AIDS 
strategic Plan as aguiding framework. (DOH,2007) 
 
Finacing HIV /AIDS programmes in low and middle income countries,shows encouraging 
results as the reduction in mortality rate and the new infections.Through this intervention the 
globall epidemic has declined from 3.0 million to 2.7 million.Generally more countries 
reported progrees in 2008, than in the previous years (UNAIDS, 2008). 
 
According to UNAIDS (2008) in 14 of the 17 countries ,the percentage of women living with 
HIV/AIDS aged 15-24, has declined .In seven countries the decline has exceded 25% target 
for 2010, set in the declaration commitment. 
 
According to Policy Projec t(2001), the scale up of the prevention of Mother to Child 
transmission of HIV/AIDS is also one important factor in the reduction of HIV/AIDS. 
Mothers who are HIV positive  should also be discouraged to be breastfeed their newborn 
especially if there are other alternatives. The provision of the milk formula in replacing breast 
feeding is a good initiatives in supporting HIV positive mothers.  
 
3.8 THE HISTORY OF THE VIRUS 
Sporadic case reports of AIDS and sero-archaeological studies date the existence of HIV to 
the 70’s. In 1981 several cases of Kaposi Sarcoma was recognised among the patient ,with 
the Centre for Disease Control (CDC)  at the same time recognizing the increased number of 
patients with Pneumocystis Carinii Pneumonia (PCP) (Avert, 2009). 
 
The condition remained with no identity, till it was called AIDS, in 1982 .Reason for this 
name was because it is acquired rather than inherited, it was rendering the immune system 
ineffective and it was a syndrome not a disease. HIV was isolated in 1983 at the Louis 
Pasteur Institute in France. World Health Organization in the same year reported the known 
cases of HIV/AIDS in America to be   2 803 (Avert, 2009). 
 
 According to Avert (2009) in 1983 again the assurance was provided on the transmission of 
HIV/AIDS to allay anxieties in communities. It was indicated that HIV can be transmitted 
through sexual intercourse, blood and Mother to Child Transmission. The knowledge on HIV 
transmission improved through the years. 
 
 
In 1986 a drug azidothymine (AZT), reported to slow down the attack of HIV/AIDS.AZT 
was produced in 1964, as a Cancer treatment which proved to be ineffective (Avert, 2009). 
According to (Avert, 2009), AIDS was first discovered in the United States of America, 
where some patient was presenting with opportunistic infections. Louis Pasteur isolated the 
human immune deficiency Virus in 1984. There are several theories on where HIV/AIDS 
comes from. The focus now is on the management and treatment of HIV/AIDS. 
 
THE DESCRIBTION OF  HIV 
 Fiqure 1. The  Structure of the Human Immuno Deficiency Virus 
 
 
The Human Immunodeficiency Virus (HIV) belongs to the classes of retroviridae or 
retroviruses and from the subgroup of lent viruses. Other Lent viruses as SIV, FIV, Visna, 
CAEV, cause diseases in monkeys, sheep, cats and goat. The virus can be seen with an 
electron microscope. For the virus to grow or reproduce, it has to infect other cells, as it 
cannot grow on its own (Avert, 2009). 
 
The virus is 100-150 billionths of a meter in diameter. Its genetic information is stored in 
RNA as compared to all organisms and more viruses, which store their genetic information 
on long strands of DNA. The virus converts its RNA to DNA. It has nine genes, while 
bacteria have 500 and humans have 20,000 to 25,000.The nine genes are gag, pol, env, tat, 
 
 
rev, nef, vif, vpr, vpu.”The first three genes carry information to make structural proteins of 
new virus and the last six code for protein that control the ability of HIV to infect a cell and 
produce new copies of the virus. The long terminal repeat at the end of each sequence of 
DNA helps to control HIV replication (Avert, 2009). 
 
The virus has an envelope (a code of fatty material). Projecting from the surface of the viral 
envelope is the 72 spikes of glycoproteins. The outer membrane glycoprotein is the called gp 
120, while the transmembrane glycoprotein is known as gp 41 (Mwangi, 2005). 
 
The structural protein called matrix protein, made of gp17, lines the inside of the viral 
enveloped. The bullet shaped capsid made of p24 covers the genetic core of the virus. 
Enclosed within the capsid is the two single stranded RNA and the viral enzymes, protease, 
integrase and reverse trancriptase. Histocompatibility complex (MHC) class I and II are of 
most importance (Avert, 2009). 
 
3.10 THE VIRAL LIFE CYCLE 
Figure 2.The Viral Life Cycle 
 
The HIV viral cycle consists of different steps, from the attachment of the virus on the host 
cell, to the budding of the virus through the infected cell to infect other cells. Pieribone 
(2006) explain the different steps of the viral life cycle as follows. 
 
 
Attachment 
The Human Immune Deficiency Virus attaches itself to the CD4 T-lymphocytes. The 
proteins on the surface of the virus attaches to the protein on the CD4 –T lymphocytes 
surface. The CD4 T –lymphocytes proteins, which serve as receptors are CD4 and beta-
chemokines receptors (CCR5 and CXCR4), while the proteins on the surface of the Human 
Immune Virus are the gp 120 and gp 41.They are also known as the antireceptors .The gp 120 
attaches to the CD4 count receptor and the chemokoines CCR5 and the CXCR4, while gp41 
facilitate the fusion (Pieribone, 2006).   
 
Fusion / Penetration. 
According to Pieribone (2006) the process of penetration and fusion follows after attachment. 
Penetration allows the nucleocapsid, which contains the genetic core of the virus to be able to 
be injected into the cytoplasm of the cell. After gp 120 attaches to the CD4, its three sugar 
coated proteins spread apart, allowing gp41, which is normally hidden by its protein to bind 
to the chemokine receptor. The process allows the viral envelope and the cell membrane to 
melts into each other. 
 
Uncoating 
Uncoating is an essential step for the virus genetic information Ribonucleic Acid (RNA),to be 
converted into the Deoxyribonucleic Acid( DNA). The nucleocapsid which encloses the RNA 
has to be dissolved, for the convertion of RNA to DNA to occur (Pieribone, 2006).   
 
Reverse Transcription 
Reverse transcription is the process, whereby the viral RNA is converted to DNA. This 
happens opposite to the usual transcription which happens in human cells, whereby DNA is 
transcribed into messenger RNA, which directs the cell‘s function. 
HIV uses its enzyme reverse transcriptase to convert its single stranded RNA into double 
stranded DNA. The enzyme uses the building blocks of DNA to make the process possible. 
These building blocks are adenine, cytosine, guanine and thiamine (Pieribone, 2006). 
 
Integration  
Integration occurs after a successful   transcription. Integration is a process whereby Viral 
DNA is inserted into the cell‘s DNA by the enzyme integrase. 
 
 
The mechanism in which HIV DNA is transported through the nuclear membrane to the 
nucleus of the host cell is unclear, though the viral protein R (PVR) is suspected to facilitate 
the movement (Pieribone, 2006).   
 
Viral Latency/Protein Synthesis  
The process follows, a successful integration of viral DNA into the host‘s DNA. At this stage 
the virus is latently infected with HIV .The viral DNA is called a provirus. This provirus is 
now waiting for activation. 
 
Once the immune cells become activated, the provirus awakens and instructs the cellular 
machinery to produce the necessary components. From the viral DNA two strands of RNA 
are constructed and transported out of the nucleus. One is translated into the subunits of HIV 
as protease, integrase, structural protein and reverse transcriptase, while the other strand 
becomes the genetic material of the new virus (Pieribone, 2006).  
 
Cleavage and Viral Assembly  
Following the production of the subunits. The subunits are separated in order to assemble in 
the new virus by the viral enzyme protease. The subunits again combine after cleavage to 
make content of the new virons. The structural subunits mesh with the cell membrane, 
allowing the nucleocapsid to take shape. Then the viral RNA, wound tightly to fit into the 
nucleocapsid (Pierebone, 2009). 
 
Budding  
This is the final step of the HIV viral cycle. The nucleocapsid merges with the cell membrane 
to make its viral envelope. The new virus buds through the cell membrane into the blood 
circulation, ready to infect other cells of the immune system (Pierebone, 2003). 
 
3.11 THE IMMUNE SYSTEM 
The immune system is the body system consisting of organs, cells, cellular product. It 
protects the body from microorganisms which are pathogenic as viruses, bacteria, fungus, 
parasites and malignancies as cancer. There are two types of immunity. Innate immunity and 
acquired immunity which is also termed adaptive immunity (Van Zyl, 2008). 
 
 
 
 
Innate Immunity  
This is the first line of defence. It is non- specific. After the pathogen enters the body, innate 
immunity is activated and responds with a local inflammation. Every time the pathogenic 
microorganism invades the body it manifests the same way, even in cases where the invader 
invades for the second time. It can at times eliminate the invader without additional 
immunity. The innate immunity includes the natural killer cell lymphocytes and the dendrite 
cells. The natural killer cell lymphocytes kill the target cell by antibody dependant cellular 
cytotoxicity (ADCC) (Mwangi, 2008). 
 
The dendrite cell localises the antigen and present it to the responsive T lymphocytes and B 
lymphocytes. The other cells of innate immunity are the monocytes, neutroplhils, oesinophils, 
basophils, macrophages, epithelial cells and tissue mast cells. The innate immunity activate 
the more complex acquired immunity (Mwangi, 2005) 
 
Acquired Immunity 
This is antigen specific, thus it responds particularly   to a particular antigen and acts against 
its components. The acquired immunity displays the memory which assists our bodies from 
not acquiring the same infection again. It has two hallmarks, the humoral and the cell 
mediated immunity also called the cellular immunity (Van zyl, 2008). 
 
Humoral Immunity 
After activation, the humoral immunity produces complex protein molecules called the 
antibodies. Cells responsible for the production of antibodies are the B lymphocytes. The 
antibodies attaches to the organism rendering them ineffective, thus preventing them from 
causing infection or it binds to this cells ,so that they can be recognised, by cells for killing 
(Mwangi, 2005). 
 
Cell mediated Immunity/Cellular Immunity. 
These ride the body of the organism that invades the host cell. The cellular immunity consists 
CD4 + T Cells also termed helper cells T cells and CD8 + T Cells also termed cytotoxic T 
cells and other cells. They are also called T Lymphocytes. When activated CD4 + T 
lymphocytes produces the cytokines which activate other cells of the immune system hence it 
is called the orchestrators of the acquired immunity. The CD 8 lymphocytes kill the infected 
 
 
cells directly. They recognise the infected cells with the components of the organism on the 
surface of the cell (Mwangi, 2005). 
 
The Immune System and the Normal Infection 
In illustrating the immune system and the normal infection, the rhino virus is used as an 
example. The rhino virus is responsible for the common cold. The virus enters the respiratory 
tract through inhalation, where it infects the epithelial tissue of the airways through the 
specific receptor. The immune system is activated by the entry of the virus into the host cell. 
Innate immunity respond with a local inflammation and attempt to control the infection, and 
at the same time triggers acquired immunity (Van Zyl, 2008). 
 
Dendrite cells carry the virus from the site of the infection to the lymph nodes, where 
acquired immunity is activated. The activated B lymphocytes  and T lymphocytes enters the 
blood stream and back to the site of the infection .Humoral and cellular Immunity occurs at 
the site of the infection. Antibodies attaches to the virus particles, while the cytolytic T cells 
(CTL) kills the infected cells, thus clearing the body from the infection (Van Zyl, 2008). 
 
The Immune System and HIV infection 
Most HIV/AIDS infection is through sexual intercourse, though HIV can be transmitted 
through infected blood and from the mother to the child during pregnancy. HIV enters 
mucosal tissues of the genital tract crosses the epithelial cells and infect the cells beneath the 
epithelium. 
 
More T lymphocytes do not appear at the site of the infection, before they are activated by the 
innate immunity.HIV binds to the migrating dentric cells, which transport the virus to the 
lymph nodes, where the virus is exposed to many T lymphocytes. Viral replication occurs 
with replication of the T lymphocytes. At the acute phase of the infection both the innate 
immunity and the acquired immunity are at work. However this phase is characterised by the 
large number of the viral particles. Though the CD 4+ T lymphocytes are being infected. The 
immune system is able to control the infection. The results being reduction in the number of 
the Viral load CD 4 + T lymphocytes (Van Zyl, 2008). 
 
At the latent phase the viral remain stable. The CD 4+ T lymphocytes, at this stage also called 
CD 4 count remain constant though still reduced. What is happening at this stage is the actual 
 
 
stimulation of the immune system by the virus antigen. The exhaustion of the immune system 
occurs as results of the continuous stimulation (Van Zyl, 2008). 
 
Because of the exhaustion the immune system, when stimulated produces it inferior 
responder cells, which are ineffective, allowing the virus to multiply again .In the absence of 
the effective immune system, without intervention the body acquire opportunistic infections 
and AIDS (Van Zyl, 2008). 
 
3.12 HIV VACCINATION 
It is envisaged that the administration of the vaccine, which is 50% effective to, 30% of the 
population, will results with HIV infection decline by more than half over the next 15 years 
and  80% of reduction in HI V infection can be observed with more effective vaccine (Avert, 
2006). 
 
On the 29th July 2009, Phase I, trial was launched in South Africa Presently worldwide there 
is no vaccine which is registered, with FDA (Food and Drug Administration. In 2009 there 29 
vaccine on trial. It is difficult to develop HIV vaccine as compared to the other vaccine. 
Reason being, no documented case of HIV recovery, where a person is healed of HIV/AIDS, 
so there is no natural mechanism for scientist to imitate, HIV attacked the orchestrator of the 
immune system, can remain latent ,occurs in several clades, and in addition to all it mutates 
rapidly (AIDS info, 2006). 
 
Vaccine is a product which is injected in the body to help the body fights the pathogen which 
causes disease. The vaccine stimulates our immune system, control and prevents infections. 
There are two types of vaccines, which are preventative and therapeutic. 
 
Therapeutic Vaccine 
These types of vaccines are designed to control HIV infection in those people who are 
already infected with HIV, thus prolonging their life and reducing the transmission rate of 
HIV/AIDS from one person to another. 
 
Preventative Vaccines 
These are designed to prevent HIV/AIDS negative people from contracting the virus. 
 
 
 
How Does the Vaccine Work? 
Every time microorganisms invade our body, the immune system is activated. The particular 
microorganism s is attacked, after the immune system defeated the microorganism or after a 
successful immune respond. The immune system remembers on how it beat the perpetrators, 
in cases of re-infection. That is displaying the memory (AIDS info, 2006). 
 
The vaccine which is the resemblance of the microorganism is injected in our body. The 
immune system therefore is activated to fight the pathogen and displaying a memory, so that 
should the body get re-infected with the same microorganism, the immune system remembers 
and attack the microorganism rapidly (AIDS info, 2006). 
 
Types of Preventative vaccines. 
Subunits/Component vaccine/Protein vaccine 
The subunits are made in the laboratory using genetic engineering techniques. They contain 
part of the virus not the whole virus. Though the subunits can activate the body’s immune 
response against HIV, they may be too weak to prompt immune effective immune response 
against future HIV infection (AIDS info, 2006). 
 
Recombinant Vector Vaccine 
The HIV virus that do not cause the disease or viruses that are weakened not to cause disease 
are used to carrier and deliver copies of HIV into the cells of the body. Once they reach the 
cell, the body produces HIV proteins, with the instruction carried in the copies of the 
gene.HIV proteins causes immune response against HIV. This method does not deliver all the 
genes, but several. The immune response may be strong in this case (AIDS info, 2006). 
 
DNA Vaccine 
The naked DNA containing HIV genes are injected in the body. The cell uses DNA to 
produce HIV protein. Anti HIV immune response is triggered by HIV proteins. 
Generally, vaccine can be used, alone or in combination, which is called prime boost strategy. 
The one type of vaccine is administered followed by the other type. The aim is to induce 
different parts of the immune system (AIDS info, 2006). 
 
 
 
 
 
Therapeutic HIV/AIDS Vaccine  
They are used in treating people who are already infected with HIV. They minimize the need 
for antiretroviral, but they are not replacing of antiretroviral. They prolong life through 
boosting the body’s immune system. 
 
Who is Eligible for Therapeutic Vaccine? 
All the People Living with HIV/AIDS with the strong immune system .The weaker immune 
system may not respond effectively to HIV therapeutic vaccine. The CD 4 count need to be > 
250 CELLS/MM3, though other trials require CD 4 count of 350cell/mm3 (AIDS info, 2006). 
 
Vaccine Side -Effects 
All the side effects for HIV vaccine are not known, but it is reported that the vaccine has the 
side effects as the other vaccines. The side effects are soreness, swelling, redness, pain at the 
site of the infection, mild flu like symptoms, (fever, chills, muscle pain or weakness, nausea, 
headache & dizziness. 
 
How are Vaccine Tested 
For an HIV vaccine to be considered safe and effective, it has to pass through three phases. 
Phase me, takes 12 to 18 months and it involves small numbers of volunteers to test the safety 
of various doses. Phase II involves hundreds of volunteers positive response and safety. 
There is also phase llB, Phase III takes three to four years, to complete, and requires 
thousands of volunteers to test for safety and effectiveness (Avert, 2006). According to (Van 
Zyl, 2008) before the trials are done on humans they are to be tested for safety. 
 
Vaccine Trial Done 
AIDSVAX-The trial was commenced in 1998 and 1999 respectively, in Thailand and 
America. In the study a single protein, was made to induce protective immunity. The study 
was completed in 2003. Results showed no beneficial results (Avert, 2006). 
 
STEP and Phambili- In 2004 Canada, USA, Australia, Peru, and South Africa in 2007, tried 
the vaccine STEP and Phambiili, which delivers HIV genes using adenovirus, which causes 
common flu. The test reached, phases II B and was discontinued. Concerns were raised that 
the infection with HIV occurred more in those who received the vaccine than those who 
received the placebo. The other  results was that the infection with HIV/AIDS occurred four 
 
 
times more in uncircumcised men, who received ,vaccine than those who received placebo 
(Avert, 2006). 
 
ALVAC / AIDSVAX- The third phase of AIDSVAX in combination with ALVAC. The trial 
started in Thailand in 2006 and completed in 2009. The ALVAX was designed to stimulate 
cellular immunity. The results of the study indicated that the vaccine prevented 31.2% of the 
infection. It was concluded that the vaccine provided modest protective effects of the vaccine. 
 
3.13 HIV DIAGNOSIS 
There are several methods for detecting HIV infection. Different methods are commonly used 
in different settings .The HIV virus can be detected through the detection of the antibodies to 
the virus, viral antigens, virus itself, viral DNA and through culture (Conradie, 2008). 
 
The Detection of the Antibody (Serology) 
There are different methods of testing for the antibodies to the virus. Those are 
Immunofluorescence (IFA) antibody assay, Enzyme Immune Assay (EIA), Rapid test and 
Saliva test. 
 
Immunofluorescence antibody Assay 
The method detects the antibody using the serum reacted with HIV infected cell (Conradie, 
2008). 
 
Enzyme Immune Assay / ELISA 
This is the preferable method of testing for HIV infection. The first generation of this assay 
utilized crude HIV 1 lysate to capture the antibodies. The second and the third generation 
used pure HIV peptides and recombinant antigens to capture antigens. It also detect the IgM 
(which is the antibody that appears early in the infection. The sensitivity with this assay is 
(>99.9%) and the specificity is (>99%).Incubation is reduced to over three weeks. The fourth 
generation of Enzyme Immune Assay detect both the antibodies and p24 antigens in a single 
test.EIA, which detect HIV antibodies in urine and Saliva, are also available. (Van Zy, 2008). 
According to (WHOM, 2004) Enzyme Immune Assay are the efficient methods for detecting 
the virus. They are used in large blood banks and for surveillance studies. 
 
 
 
 
Rapid HIV Test. 
These are commonly used in South Africa. They do not require intensive training. The 
specimen is achieved by the prick on the finger .There are rapid test that uses saliva and 
urine. The turnaround   time is less than ten minutes in some rapid test. There are four types 
of this assay, which are agglutination, comb/dipstick, flow through membrane and lateral 
flow membrane (WHO, 2004). 
 
Western Blot 
This assay used to be regarded as the preferable methods for conforming HIV infection but it 
is no longer suitable as it lacks sensitivity   when comparing it to the enzyme Immune assay 
(Van Zyl, 2008). 
 
Virus Detection 
P 24 antigen  
This is also used to test HIV infection .The antigen can be detected 14-21 days after infection. 
It is present in the early stage of the infection and falls below undetectable level and 
detectable again in the last stage of the disease; hence it is not suitable for large scale 
screening assay (Van Zyl, 2008). 
 
Virus Isolation in a Cell Culture 
Cell culture means growing living cells in the laboratory. This methods is used in research or 
when dealing with problematic cases. There are only two laboratories in South Africa which 
uses this methods and they are called Bio safety Level 3 (BSL 3).Infection control measures 
in these laboratories are highly utilized and the air moves from clean area to dirty areas, doors 
are self closing .The air is filtered before it goes outside to render it pathogen free (Van Zyl, 
2008) 
 
In culturing HIV, the lymphocytes from the infected individual, is added to the lymphocytes 
of an HIV negative individual. After two to three week a cytopathic effects is observed. 
These are when the donor lymphocytes change in appearance, as a results of the replication of 
the virus from the infected lymphocytes. The availability of the p24 antigen and the enzyme 
reverse transcriptase in to the culture indicate the presence of the HI virus (Van zyl, 2008). 
 
 
 
 
The Electron Microscopy. 
In order to detect the virus using electron microscopy, one million virus particles per ml of 
blood is required (Van Zyl, 2008).  
 
Molecular Technique and Nucleic Acid Testing 
Polymerase Chain Reaction (PCR) 
The methods are able to detect HIV infection approximately 10-16 days after infection. The 
assay detects the genetic code of the virus using amplification/copying methods. In most 
cases PCR is used to diagnose HIV infection in infant born to HIV/AIDS mothers. The PCR 
is also able to detect viral load in the blood (Van Zyl, 2008). 
 
3.14 HIV TYPES, GROUPS AND SUBTYPE 
HIV is divided into types, groups and subtypes. There are two types of HIV which are, HVI 1 
and HIV 2.HIV1 is responsible for most of the infections.HIV 2  is not easily transmitted and 
the progression from infection to illness is long.HIV 1 is divided into groups as M 
group(Major), O group(Outliner), N group and P group. P was discovered 2009 (.Avert, 
2009). 
 
90% of HIV infection belongs to the M group. These group have nine subtypes, namely 
subtype A, B, C, D, F, G, H, J, K. Hybrid Virus occur as a results of the combination of the 
two different subtypes .Most of these strains do not survive well, but the Circulating 
Recombinant Forms (CRF’s)  survive. This is those hybrid viruses which infect more than 
one person (Avert, 2009). 
 
Circulating Recombinant Forms (CRF’s) are part of M group. The example of CRF’s is 
CRFA/B which is a combination of subtype A and subtype B. The hybridization between 
subtypes a and other ‘parents’ subtype E is known as CRF A/E. Other confuses it and name it 
subtype E. The correct identification of this CRF is CRF01_ AE. A very complex CRF A, G, 
H, and K was isolated in Cyprus (Avert 2009). 
 
 
 
 
 
 
 
Figure 3. Subtypes and their Predominant Countries 
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3.15 ANTIRETROVIRALS 
Antiretrovirals are the HIV treatment which’s goal is to suppress the viral replication, 
rejuvenate the immune function, improve the quality of life of those who are infected with 
HIV/AIDS and reduces the transmission of HIV (Van Dyk, 2004). 
 
 According to UNAIDS (2008) the increased access to antiretroviral over the last ten years 
has resulted with the reduction in the number of HIV/AIDS death. The number of people 
receiving antiretroviral in low and middle income countries has increased tenfold, reaching 3 
million people by the end of 2010. Antiretrovirals, rejuvenated households, community and 
 
 
the improved quality of life, the increased access to antiretroviral is in line with the 
declaration commitment to make HIV treatment available in resource limited setting. In 2008 
South Africa exceeded a target of 180000 of people living with HIV/AIDS. 
 
Many countries make effort to increase HIV treatment access. Namibia treatment effort   was 
1% in 2003, and in 2007 88% of people in need of antiretroviral where on antiretroviral. 
Rwanda treatment access was increased from 1% in 2003 to 71% in 2007 and in Thailand 
antiretroviral therapy coverage rose from 45 in 2003 to 6% in 2007 (UNAIDS, 2008). 
 
South Africa in increasing access to antiretroviral has accredited Comprehensive Care 
Management and Treatment (CCMT) of HIV services in all the provinces, there are lot of 
CCMT in South Africa which are still in the process of being accredited. The challenge in 
some of the CCMT is the lack of resources, and skills in attaining the declaration 
commitment. Most CCMT rely on Non- Governmental Organization for the resources.  
 
South Africa is among  countries which reached 25%-49% of coverage of antiretroviral 
therapy among adults and children with advanced HIV and 50%- 75%, coverage of 
antiretroviral for the prevention of  Mother to Child Transmission of HIV/AIDS (UNAIDS, 
2008). 
 
Donors as PEPFAR help finance   antiretroviral treatment. PEPFAR‘s goal was to reach 2.5 
million people with treatment by 2012. UNTAID also plays a role in scaling up paediatric 
treatment programmes. Other companies as Global Business Coalition on HIV/AIDS and 
Setswana in Botswana assist in scaling up treatment. Faith Based Organization also plays a 
role in scaling up treatment in some other countries (UNAIDS, 2008). 
 
According to the study done in Denmark a young men newly diagnosed with HIV/AIDS is 
likely to leave additional 35 years with available treatment. Another study in the United 
Kingdom indicates that the median time for treatment failure for a patient on first line 
regimen that include one or more protease inhibitors ranges from 4.3 years to 6.5 years, while 
the median time of the patient started on the regimen containing two Nucleoside Reverse 
Transcriptase Inhibitors and one Non- Nucleoside Reverse Transcriptase Inhibitor is 13.2 
years. Treatment impact is reduced in people who were diagnosed late (UNAIDS, 2008). 
 
 
WHO recommends that countries use standardized antiretroviral drug regimen consisting of 
fixed dose combination. First line regimen to include two Nucleoside Reverse Transcriptase 
Inhibitors and one Non -Nucleoside Reverse Transcriptase Inhibitors. The second therapy to 
include a protease Inhibitor boasted with ritonavir. Most countries are designing their 
HIV/AIDS treatment guidelines in line with WHO recommendation (UNAIDS 2008). 
 
WHO recommend that antiretroviral be started when the CD4 count falls below 350 cell per 
mm3 and  that the patient with  a CD 4 count of below 200, be put on treatment. The United 
States department of Health recommend the initiation of antiretroviral in patient with a CD 4 
count of less than 350 ml per mm3 and that treatment be commenced in the entire patient 
who experienced AIDS defining opportunistic illness (UNAIDS 2008). 
 
According to the South African National HIV guidelines antiretroviral can be commenced 
after treatment readiness assessment, when the CD 4 count is ≤ 200 irrespective of the stage 
and when the patient is on   stage 4 of the WHO HIV staging irrespective of the CD 4 count. 
The antiretroviral are use in the prevention of HIV transmission and the treatment of 
HIV/AIDS has the therapeutic and preventative function. Antiretrovirals in fighting 
HIV/AIDS target their action on different steps of the life cycle. We have different classes of 
antiretroviral. Other classes are already being used, while others are on trials or still being 
researched.  
 
 It is essential that more antiretroviral studies are conducted to develop antiretroviral which 
are simple, less toxic and affordable reduce the burden of the disease (UNAIDS, 2008). 
 
Classes of Antiretrovirals 
Entry Inhibitors- They is aiming at blocking the interaction of the CD4 T- lymphocytes 
receptors with the ant receptors of the virus, by blocking the receptor sites (Pierebone, 2006). 
Fusion or Penetration Inhibitors-The fusion inhibitors aims at preventing the gp41 from 
binding with the chemokine receptor. The drugs are to be approved by the FDA. They are 
Enfurvirtide & Fuzeon (Pierebone, 2006). 
 
Reverse Transcriptase Inhibitors-These drugs prevent HIV enzyme reverse transcriptase from 
using nucleotide and also attaches to this enzyme to prevent it from functioning. The 
nucleoside and nucleotide reverse transcriptase inhibitors contain a faulty imitation of the 
 
 
nucleotide. The imitation building blocks are inserted in the growing chain of DNA instead of 
the building blocks of DNA. These prevent the double strand of DNA to be completely 
formed. Non nucleoside reverse transcriptase inhibitors attaches to the enzyme to render it 
ineffective (Pierebone, 2006). 
 
Integrase Inhibitors- they   inhibiting the pre integration complex from entering the DNA 
(Pierebone, 2006).  
Protease Inhibitors -They binds with the protease enzyme making it difficult for the enzyme 
to cleave or separate the subunits (Pierebone, 2006). 
Zinc Finger Inhibitors-These are still being researches and they are aiming at interfering with 
the packaging of the RNA into the nucleocapsid (Pierebone, 2006). 
Potential Antiretroviral agents - are aiming at inhibiting the viral RNA (Pierobone, 2006). 
 
3.15.1 ANTIRETROVIRALS IN THE PREVENTION OF HIV 
 
The Post Exposure Prophylaxis (PEP) 
The Post Exposure Prophylaxis in regards to HIV/AIDS is the treatment given to those who 
are exposed to HI Virus, in order to prevent them from acquiring the infection. The individual 
can be exposed to the virus, accidentally through occupational exposure or during assaults, as 
rape. For an example the health care worker can be picked by the contaminated sharp or 
instrument from the HIV/AIDS infected patient .The sharps may be contaminated from 
cerebrospinal, peritoneal, synovial, pericardial fluid, blood, semen, vaginal secretions and 
other fluid from the body. 
 
More health care workers experience occupational exposure to HIV/AIDS. The study done in 
West Africa report that 45% of health workers sustained accidental blood exposure and 60% 
of the cases were not reported .In a study done in South Africa at Chris Hani Hospital, 69% 
of interns sustained one percutaneous, 45% sustained mucocutaneous injuries, while over 
60% of these cases were not reported (SAHIVSOC, 2008). 
 
Who is Eligible for PEP? 
The matter of who qualifies for PEP, depend on different institutions. The South African 
national HIV/AIDS guideline, in their discussion of PEP, mentions rape victims and those 
 
 
exposed to occupational hazards. The protocol is not clear about those who are exposed to 
HIV/AIDS without being raped (DOH, 2004). 
 
According to (SAHIVSOC, 2008) Individual who is exposed to HIV/AIDS either sexual, 
occupational or otherwise qualifies for PEP.  
 
The Procedure in Regards to PEP (Occupational Exposure) 
The patient and the exposed health care professional are tested for HIV. Pre- counselling is 
done prior HIV testing. After receiving the results, Post Counselling is provided. In cases 
where the results of the patient are negative, there is no need for PEP. Where there is a 
suspicion that the client is on window period, HIV is tested using Polymerase Chain Reaction 
(PCR). The method tests for viral DNA not the antibodies (DOH, 2004). 
 
In cases where the patient is HIV Positive, and the health care worker is HIV positive, they 
are both referred for HAART. PEP in patient who is already HIV can jeopardise future 
treatment. The PEP is initiated when the exposed worker is HIV negative and the patient is 
HIV positive (DOH, 2004). 
 
In prescribing PEP an assessment need to made on the extend of the risk to contract 
HIV/AIDS. The risk include an exposure to large inoculums of infected blood, these will be 
indicated, by the visible injury and visible blood on the device. Terminal infection on the 
source patient poses a risk to occupational exposure (DOH, 2008). 
 
The Prevention and Control of Occupational Exposure  
The occupational exposure to HIV/AIDS can be controlled and managed especially with 
availability of the infection control protocol. The already contaminated needles with body 
fluid need to be disposed in a biohazard bin. The needle is not to be recapped. In Intensive 
Care Unit the ratio of bin to bed need to be at least 1:1 in open ward 2:1. Once the biohazard 
bin is ¾ full, must be exposed. The sterilization of surgical equipment also reduce the risk of 
occupational exposure to HIV/AIDS (SAHIV, 2008). 
 
 
 
 
 
 
PEP and Sexual Assaults 
After a report of sexual assaults, the adult receive counselling on the possibilities of infection. 
There are again Pre Counselled prior HIV infection. After receiving results Post Counselling 
is offered. 
 
In cases the victims do not want to know their HIV/AIDS status they are allowed to presents 
within 72 hours to receive, their Post Exposure Prophylaxis. Adherence Counselling ,support 
and anxiety management are  very significant .Especially with sexual assaults cases as this 
patient get other treatment as pregnancy prophylaxis and sexually transmitted infection (STI) 
syndrome management (SAHIVSOC, 2008). 
 
Children are given special services different from the adult, by providers with special 
expertise in managing sexual assaults in children (DOH, 2004). The sexual assaults victims 
receive 2-drug regimens and 3-drug regimen in cases of risk as multiple perpetrators, obvious 
trauma to the genital area, anal penetration and when the status of the perpetrators are known 
to be positive. Post Exposure Prophylaxis regimens according to the South African National 
HIV/AIDS Guidelines. 
 
Name of the Drug Dose Duration 
Zidovudine (AZT) 
 
300mg bd 28 days 
Lamivudine(3TC) 
 
150 mg bd 28 days 
 
In cases of higher risk exposure Protease Inhibitor Kaletra is added to the above regimen. 
 
Name of the Drug Dose Duration 
Liponavir/ Ritonavir 
(Kaletra) 
III/III bd 28 days 
 
 
 
 
 
 
Regimens to be used with PEP According to the (SAHIVSOC, 2008) 
Twice a day treatment 
Staudinger (d4T)+ Lamivudine(3TC) 
 
Zidovudine (AZT) + Lamivudine (3TC) 
 
 
 
Once a day treatment 
Tenofovir(TDF) +Emtricitabine(FT 
 
 
Third Agent in Cases of 3-Drug Regimen 
Twice a day treatment. 
Lopinavir / Ritonavir 
 
Saquinavir  / Ritonavir (400 /100 bd)  
 
 
Once a Day Treatment  
Efavirenz 
 
Atazanavir  / Ritonavir 
 
Lopinavir  / Ritonavir(800 /200 ) 
 
 
The Prevention of Mother to Child Transmission of HIV/AIDS (PMTCT) 
This is the administration of dual therapy to HIV positive pregnant mothers at 28 weeks to 
reduce the risk of transmission of HIV from the mother to the child. After the positive HIV 
results. Mothers are prescribed Zidovudine (AZT) 300 mg twice a day while still waiting for 
the results of CD4 count. The woman with the CD 4 results of ≤ 200 is referred for HAART 
 
 
and the one with the results of > 200 continue with Zidovudine 300 mg bd till labour (Seedat, 
2008). 
 
While in labour the woman is given Sd (NVP) and the women continue with AZT 300 mg 
every three hours. Immediately after the delivery of the baby, dual therapy is stopped. The 
focus is now on the newborn (DOH, 2008). 
 
Infant immediately after birth are given Sd (NVP) and Zidovudine is also administered at 
birth and prescribed for 7 days and 28 days. Zidovudine is administered for 28 days for those 
infants of mothers who received HAART and dual therapy for < 4 weeks, Sd (NVP) during 
labour and those who never received antiretroviral. 7 days treatment is prescribed for infants 
of mothers of mothers who received dual therapy   for ≥ 4 weeks (DOH, 2008).The flow 
diagram below illustrate PMTCT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:   Prevention of Mother to Child Transmission of HIV/AIDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 weeks 
pregnant and HIV 
positive 
If CD 4 count ≤ 200, or 
WHO stage 4 
Prescribe AZT 300mg 
bd 
-referred for CCMT 
If CD 4 count 
>200, 
-Prescribe AZT 
300mg bd till 
labour 
During Labour 
-AZT 300mg 3hrly 
-Sd NVP 
 
After Labour 
For neonate born to mothers, 
-who received dual therapy 
and HAART for <4 weeks 
-who received on only SdNVP 
-who never received ARV’s 
Prescribe SdNVP and AZT for 
28 days 
For neonate born to mothers  
 
–who received dual therapy 
for ≥ 4 weeks 
Prescribe SdNVP and AZT 
for 7 days. 
 
 
3.15.2 ANTIRETROVIRALS IN THE TREATMENT OF HIV/AIDS 
South African public sectors use three regimens as recommended by the World Health 
Organization, which are regimen 1a, 1b and regimen 2. Mixed regimens are also part of the 
treatment strategy. 
 
Figure 5.Regimens According to the South African National HIV/AIDS Guideline 
1A 
 
1B 2 
Stavudine(D4T) 
 
Stavudine(D4T) Zidovudine(AZT) 
Lamivudine (3TC) 
 
Lamivudine (3TC) Didanosine (DDI) 
Efavirenz  (EFV) Nevirapine(NVP) Lopinavir/Ritonavir(Kaletra) 
 
 
N.B With development Kaletra is replaced in many cases by Alluvia and there is a 
combination of AZT+ 3TC called Lamzid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.15.3 ANTIRETROVIRALS, CLASSES, SIDE EFFECTS AND SPECIAL 
CONSIDERATIONS IN SOUTH AFRICA 
 
Figure 6. Antiretrovirals, Classes, Side effects and Special Considerations. 
 
             NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
Name of the drug Side effect  Special Consideration  
 
 
Stavudine (d4T) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral neuropathy- Tingling 
sensation of legs 
 
Lactic Acidosis 
Persistent Nausea ,vomiting and 
abdominal pain 
Shortness of breath 
Tiredness (unexplained) 
Weight loss 
Cold and blue( hands, feet ) 
Abnormal heart beat 
Rapid breathing 
 
Lip atrophy- Loss of fat on: 
Face (sunken cheeks, temples and 
eyes) 
Veins more visible on legs and arm  
Buttocks 
 
Few side effects- slight peripheral 
neuropathy, rash and pancreatitis 
 
Initial nausea, vomiting, headache, 
myalgia- all fades with time 
Anaemia -paleness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lamivudine (3TC) 
 
 
 
Zidovudine(AZT) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
DIDANOSINE(DDI) 
 
 
 
 
 
 
 
Initial nausea, vomiting and headache, 
pancreatitis  (may be fatal ) 
Abdominal discomfort 
 
 
 
 
 
 
 
To be taken without food. 
(30 minutes before or after food) 
To be doubled if client weight is 
above 60 kg 
 
 
 
 
 
 
 
 
NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS 
Name of the drug Side Effects  Precaution 
 
Tinofovir (TDF) 
 
 
 
 
 
Nephrotoxicity 
 
 
 
 
 
 
NON- NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR 
Name of the drug Side effects Precautions 
 
 
Efavirenz (EFV) 
 
 
 
 
Loss of concentration, insomnia, 
dizziness, delusions, inappropriate 
behaviour, abnormal dreams. 
Hallucinations. 
Rash common in first six weeks. 
Teratogenic effects- may affect the fetus 
during  
              
 
Don’t use in pregnancy. 
To be avoided by clients doing 
night duty. 
Don’t use with history of mental 
illness or depression 
 
 
 
Nevirapine (NVP) 
 
 
Mild to moderate rash within the first 6 
weeks. 
Hepatitis – liver disease 
Do’s 
2 weekly Liver Function 
Test(LFT) 
4 weekly LFT 
8 weekly LFT 
3 monthly LFT then  
6 monthly LFT 
Stop NVP if liver enzymes are 
increasing 
To be changed if the client 
contract TB 
6 
 
 
Not to be used with CD4 of >250 
in women and >400 in men 
Generally all Regimens 1b can be 
taken with or without food. 
 
 
 
 
PROTEASE INHIBITORS 
Name of the drug 
 
Side effects Precaution 
 
Lopinavir / Ritonavir 
(Kaletra) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperadiposity (fat accumulation) at: 
The back of the neck or upper 
shoulder( buffalo hump) 
Abdomen (protease paunchor ,crixivan 
potbelly) 
Breast in both men and women 
Lipomas (fatty growth in different 
parts of the body. 
 
Hyperlipidemia – increase level of 
cholesterol in blood 
GI upset : Diarhea,Nausea,Vomitting 
     Hyperglycaemia 
Headache 
asthenia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk of developing hyperlipidemia can 
be controlled by: 
Quitting smoking 
Avoiding alcohol 
Exercise 
Control of blood pressure 
Low fat diet 
Kaletra to be avoided in people with 
history of high cholesterol.  
 
 
Generally kaletra is to be refrigerated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alluvia 
 
 
 
 
 
 
 
 
 
 
 
 
or on floors in cases where there is no 
refrigerator. 
To be doubled in cases the client 
contracted TB 
Can be taken with or without food 
 
 
 
This replaces Kaletra, in many cases 
though Kaletra is still used. 
 
 
 
 
 
 
OTHER ARV’S RARELY USED IN THE PUBLIC SECTOR OR NOT USED AT ALL 
PROTEASE INHIBITOR 
Name of the drug 
 
Side effects Precaution 
Indinavir 
 
 
 
 
 
 
 
 
 
Use in combination with 
Ritonavir to increase half life. 
No food restrictions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nelfinavir 
 
 
 
 
 
 
 
 
 
Nephrolithiasis: kidney Stones 
Unconjugated hyperbilirubinaemia 
GI disturbances:nausea, diarrhea 
Hair loss 
Hyperglycemia (low potential) 
Headache 
Dyslipidaemia(Moderate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diarrhoea 
Nausea 
Vomiting 
Abdominal Pains 
 
Hyperglycaemia(low potential) 
 
Dyslipidaemia (low potential) 
 
 
 
←Drink lot of fluid, at  least 1.5 L 
a day 
 
 
←Monitor Blood Glucose 
 
←Risk of developing 
hyperlipidemia can be controlled 
by: 
Quitting smoking 
Avoiding alcohol 
Exercise 
Control of blood pressure 
Low fat diet 
 
Renders oral contraceptives 
ineffective, use other alternative 
Take this medication with meals 
or snacks 
←Monitor Blood Glucose 
 
←Risk of developing 
hyperlipidemia can be controlled 
by: 
Quitting smoking 
Avoiding alcohol 
Exercise 
Control of blood pressure 
Low fat diet 
 
 
 
 
 
 
Ritonavir 
 
 
 
 
 
 
 
 
 
 
 
 
Atazanavir 
 
 
 
 
 
Saquinavir 
 
 
 
 
 
 
 
 
 
 
 
 
Fosamprenavir 
Hyperglycaemia(High Potential) 
 
Dyslipidaemia 
 
 
 
Paraesthesiae 
Fatique 
Hepatitis 
Taste perversion 
Diarrhoea 
Abdominal Pains 
 
 
Dyslipidaemia(low potential 
Unconjagated  
hyperbilirubinaemia 
Hyperglycaemia 
 
 
Mild GI disturbances 
 
Hyperglycaemia(high potential) 
 
Dyslipidaemia (low potential) 
Headache 
Elevated tranminases 
Nausea 
Diarrhoea 
Abdominal Pains 
 
 
 
←Monitor Blood Glucose 
 
←Risk of developing hyperlipidemia 
can be controlled by: 
Quitting smoking 
Avoiding alcohol 
Exercise 
Control of blood pressure 
Low fat diet 
 
 
 
 
 
 
 
Take with fatty meal or up to 2 hours 
after meals 
To be boosted with Ritonavir 
 
 
Rash, 
Headache 
GI upset 
Hyperglycaemia 
Dyslipidaemia 
 
 
 
 
 
 
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR  
Name of the drug  Side effects Precautions 
 
Abacavir (ABC) 
 
 
 
 
 
Emtricitabine(FTC) 
 
 
 
Hypersensitivity reaction:fever,rash 
 Gastrointestinal (GI ) upset, 
Hyperlactataemia(Low potential) 
Cough 
 
 
 Hyperlactataemia(Low potential) 
GI upset 
Hypersentitivity reaction 
Hyperpigmentation 
 
 
 
 
 
(SAHIVSOC, 2008; AFA, 2007; DOH, 2004)  
 
According to HIV Channel (2009) Entry inhibitors as maraviroc, fusion inhibitor as 
infuvirtide and HIV integrase strand transfer inhibitor as raltegravir were recently approved 
by the FDA. 
 
 
3.16 ADHERENCE 
 
3.16.1 ADHERENCE TO ANTIRETROVIRALS. 
Adherence is defined as the extend which the clients follows prescribed treatment, which was 
prescribed in a consultative partnership, between the clients and the health care worker 
(Saloner, 2005). 
 
 According to (Fomundam, 2008; NRC, 2008) adherence means taking the medication the 
way it was prescribed. It means taking medication, keeping appointment, understanding 
preventative measures as dieting, exercising, substance, use, changing inappropriate 
behaviour. Adherence is the determinant of survival for the patient on antiretroviral; 
adherence is second to CD 4 count cell count as the predictor to the progression of AIDS. 
There is a requirement of up to 100% adherence for the optimal viral suppression.   
 
3.16.2 PREDICTORS OF ADHERENCE 
 According to Machinery and Bengsburg (2008) full understanding of the predictors of 
adherence can assist the health care providers to approach non adherence successfully. The 
first predictor is patient variables. These are socio demographic factors as age, gender, race, 
ethnicity, income, education, literacy, housing status, insurance status HIV risk factors and 
psychological factors as mental health, substance use, social climate and support, knowledge 
and attitudes about HIV and its treatment. 
 
There is conflicting evidence on the association between the socio demographic factors and 
the adherence behaviour. For example young age, ethnicity and lower income, lower literacy 
and unstable housing are associated with non – adherence , in research rich setting, while 
gender, educational level, insurance status and HIV risk factors are associated with adherence 
behaviour ( Machtinger  et al., 2008). 
 
Treatment Regimen 
According to Machtinger et al. (2008) factors as the number of tablets prescribed the 
complexity of the regimen, the specific type of the antiretroviral and the medication side 
effects are discussed below in relation to adherence behaviour. Non adherence is associated 
with the complexity of the regimen and the side effects. One – daily regimen is reported to 
have a good impact on adherence. Adjusting the regimen to the patient life style is the 
 
 
determinant of adherence. The specific type of a pill is not associated with adherence 
behaviour. 
 
Disease Characteristics. 
There is an inconsistence relationship between adherence behaviour and disease 
characteristic, which is the length of the infection and the stage of the infection. Some studies 
report increased adherence among patient with history of opportunistic infection, as the 
experience of infection encourages them to adhere to medication in order to become healthy 
and not to ever find them in a state they were before. Other studies found the relationship 
between non adherence and lower CD 4 count (Machtinger et al., 2008). 
 
Patient Provider Relationship. 
Referring to this case there are several issues which may affect adherence as overall 
satisfaction and trust in the clinic staff or health providers. The patient ‘s opinion on 
competence, willingness  of the health provider, the involvement of the patient in decision 
making, warmth, openness, corporation the concordance of race / ethnicity of the patient  and 
the provider and the adequacy of referrals (Machinery  et al., 2008). 
 
According to Machinery et al. (2008) the patient‘s trust in the physician was associated with 
increased adherence in two studies of incarcerated women. Other studied illustrated good 
adherence in cases where the client   had a long steady and trusting relationship with a single 
provider. 
 
Clinical Setting 
Machinery et al. (2008) adherence may be influenced by factors as accesses to ongoing 
primary care, involvement in an adherence programme, availability of transportation, 
availability of childcare, therapeutic environment, convenience appointment, perceived 
confidentiality, satisfaction with the past experience in the health system. Studies illustrate 
that dissatisfaction with the prior experience in the health system, is associated with non 
adherence. 
 
3.16.3 NON- ADHERENCE TO ANTIRETROVIRALS  
Non adherence to antiretroviral put the patient at risk of AIDS progression, treatment failure 
as well as the risk of developing drug resistance. Drug resistant leave the individual with 
 
 
limited treatment options. However non adherence is not only the determinants of treatment 
failure. There are other factors as genetic differences in drug metabolism, severe baseline 
immune suppression, prior drug resistance and concurrent opportunistic infection (Machinery 
& Bangs berg, 2007). 
 
Clients commonly gives the reasons for non adherence as side effects, regimen too complex, 
dosing not fitting with the daily schedule, forgetfulness, not having time to take medication, 
oversleeping, missing dose, left medication while away from home, lack of basic information 
on adherence, uncomfortable taking medication in front of the family friends and co-workers 
(NRC, 2008). 
 
Factors that are associated with poor adherence in the United States and Europe are as 
follows depression, active alcohol, drug use, low literacy, lack of social support ,lack of 
belief in treatment efficacy, unstable housing, Competing priorities(e.g. housing, childcare, 
food, work (NRC,2008). 
 
According to Machinery et al. (2008) non adherence is associated with psychological factors, 
psychiatric conditions, active drug use and events as lack of basic drug literacy. The drug 
literacy in this case refers to the identification of the medication and the description of the 
relationship between adherence and drug resistance. 
 
3.16.4 BARRIERS TO ADHERENCE TO ANTIRETROVIRALS 
According to the study in Botswana which ‘s aim was to elicit principal barriers to adherence 
to antiretroviral, 48 % of subject reported that they have missed their dose because of 
financial constraints, 24% listed forgetting as the primary reason for non adherence. Other 
barriers included running out of medication (17%), travel migration (13%), side effect (12%) 
being to busy12%. Weiser, Wolfe, Bangsberg, Thior, Gilbert, Makhema, Kebaabetswe, 
Dickenson, Mompati, Essex, Marlink (2003). 
 
 69% of the respondents did not disclose to their family, 94% kept HIV /AIDS status as secret 
to the community. 32% reported that they may lose their job, if they can disclose their status 
to their employers. The participants did not disclose to their families, as they were afraid they 
will be rejected, ostracized or lose their marriage. Only 15% of the participants reported 
stigma as a barrier to adherence (Weiser et al., 2003). 
 
 
According to Nakiyemba, Akurut, Kwasa and Oyaba (2007) distance, transport and finance 
in order to access the health facility in Uganda were a barrier to adherence. Some of the 
participants reported they had to travel 50-130km in order to access the health services and 
some has to cross the river. The participants reported difficulty in getting money for transport 
hence they did not come for their appointment sometimes. Other barriers to adherence 
mentioned where poverty, waiting time. Stigma and discrimination were not reported as a 
huge barrier to adherence though it exists. 
 
3.16.5 VIROLOGICAL AND CLINICAL IMPLICATION OF ADHERENCE 
 
Virological Implications of Adherence 
Full viral suppression lead to maximal reconstitution and the maintenance of the immune 
system and minimize the emergence of drug resistant virus. It is envisaged that the ≥95 % 
adherence is necessary for the full suppression of the virus. The near perfect ≥95 % requires 
that the patient does not miss or substantially delay three doses of medication. It is a 
challenge for most of the patient to maintain this level of adherence (Machinery et al., 2008). 
In a study of 866 participants done in British Columbia. It was found out that near perfect 
level of adherence is required for reliable viral suppression. Of 502 participants at 95-100%  
adherence 84% achieved plasma viral load of < 500 copies/ml whereas 64% of the 64 
subjects at 90 - < 95%  achieved level of suppression(p=0.001) (Machinery  et al., 2008). 
 
The association between adherence and virological control was investigated, in a study of 34 
HIV positive patients, who were taking antiretroviral including protease inhibitors over 3 
months. It was found out that 10% decrease in adherence lead to the doubling of the viral 
load. Small difference in adherence can lead to major differences in virological control. 
Though not thoroughly studied it is reported that regimens as ritonavir – boosted PI based 
and Nucleoside Reverse Transcriptase Inhibitors may suppress the virus even at lower rate of 
adherence (Machtinger et al., 2008). 
 
Clinical Implications of Adherence 
Many studies has proven adherence to be associated with clinical outcomes and the 
laboratory markers as CD 4 count. In a prospective cohort study of 1,095 subjects, who were 
enrolled in randomized multicentre trials of initial and salvage therapy. It was found out that 
patient who reported 100% , 80-99%, and 0-79 % adherence rate had a CD 4 count 
 
 
improvement of 179,159, 53 cells/uL respectively from baseline to 12 months( Machtinger  et 
al., 2008). 
 
 According to Machtinger et al. (2008) non- adherence is associated with increased mortality. 
A study which was measuring adherence discovered that no patient with >90 adherence 
progressed to AIDS over the 13 months follow- up  period, compared to those who are 51-
90% adherence and 41with ≤ 50% adherence. Non-adherence in other studies was associated 
with hospitalization and mortality. 
 
3.16.6 TREATMENT READINESS ASSESMENT  
In their National HIV/AIDS guideline the Department of Health requires that before starting 
the patient on antiretroviral, the drug readiness must be assessed. The drug readiness 
assessment includes medical, social and psychological assessment. The medical assessment 
includes the treatment of opportunistic infections and the assessment of the CD 4 count. The 
social assessment incorporates the issues as the home environment and whether the clients 
have disclosed. It is recommended by the national HIV /AIDS guideline that the patient must 
at least disclose to one person before starting antiretroviral (DOH, 2008). 
 
The psychological assessment assesses whether the patient accepted the HIV status. All the 
assessment has to be achieved in three sessions that the patient is appointed to attend. During 
these three sessions the patient is again assessed for the knowledge on the information given. 
The cotrimoxazole pill count is performed.  The multidisciplinary team play a role in these 
sessions (DOH, 2008).  
 
According to Saloner (2005) the medical assessment during drug readiness assessment should 
includes gynaecological examination. Information on the adherence history of the patient will 
be essentials, for example it will be appropriate to ask if the clients was ever on long term 
treatment as hypertensive treatment or contraceptive pills ,in order to plan for adherence 
intervention. 
 
Different factors which may influence adherence behaviour need to be assessed, for example 
life style, occupation, travel, routine and sleep pattern. The information on the kind of work, 
the patient is doing will assist in the planning of the treatment. A person who works night 
 
 
duty may not be placed on the regimen containing efavirenz, as it can lead to drowsiness and 
lack of concentration. 
 
According to NRC (2008) Treatment readiness assessment is essential before starting the 
patient on antiretroviral. Patient ‘willingness  to start antiretroviral, ability to take long term 
treatment and willingness to accept antiretroviral side effects are part of treatment assessment 
Patient’s support system as the family and friends plays an important role in assisting the 
patient to adhere to antiretroviral. They remind the patient on the time of taking medication 
and help the clients deal with the side effects. 
 
Given the information on side effects, the patient may describe the side effects that she/he is 
willing to accept thus   assisting the physician tailoring selection of antiretroviral for 
individual patient. Information is provided on the strategies for the management of side 
effects, before starting with the treatment. 
 
In assessing whether the clients will be able to adhere to antiretroviral, adherence trials can be 
done using placebo tablets and jelly beans. The trial will help patient understand what it 
means to take the tablets daily and adjust the lifestyle to accommodate the regimens 
prescribed. The disadvantage of the placebo trials is that they do not have the side effects as 
the antiretroviral (NRC, 2007). 
 
3.16.7 ADHERENCE SUPPORT 
Close follow up of the patient is significant, especially after the first few days of starting the 
therapy. This will assist the care providers to identify side effects, asses the comprehension 
on the treatment and assist identify concerns which may become adherence barriers. The 
follow up can be done either by the telephone, clinic visit, or other forms of contact. It is 
essential to deal with each and every person as an individual to optimize outcomes. 
Pharmacist, peer counsellors, support groups, adherence counsellors, behavioural 
intervention, community based case managers, are useful in supporting adherence to 
antiretroviral (NCR, 2008). 
 
Multidisciplinary teams that include nurses, case managers, nutritionist and pharmacist are, in 
which health care provider focuses on adherence during their session with the clients are 
effective way of supporting adherence. It envisaged that adherence decline in cases where 
 
 
focus intervention is discontinued. During follow up visit it is important to encourage those 
who are adhering well and share improvement in patient‘s health, for example the 
improvement in CD4 count and viral load (NCR, 2008). 
 
Empowering those living with HIV/AIDS through skill development can play a role in 
enhancing adherence. It will be difficult for a hungry person to take pills all the time, besides 
some of the antiretroviral, has some dietary restriction. An empowered individual can take of 
his own needs. The provision of grants will be necessary for those clients who are sick and 
they cannot do for themselves. The participation in support group and the availability of the 
support partner will enhance adherence to antiretroviral. 
 
Ongoing adherence can help enhance adherence. Pill count and patient self report at every 
appointment help to identify non adherent patient and these assists in early intervention. 
 
Devices to Support Adherence 
Medication organizers as pill boxes and medisets are good devices for use in adherence 
support. The clients fill them every week in such a way she/he is able to recognize the missed 
doses. Reminder devices such as alarm watches, beepers, cell phones and alarms are useful in 
reminding the patient when to take medication. Diary can be used to record medication 
already taken. Visual medication schedule, with the images of medication on them, are 
effective as reminding the patient of tablets (NCR, 2008). 
 
A particular television programme can be selected, to remind the clients about taking the 
medication however the problem may occur if the programme is discontinued or has changed 
its time. Many people who are reminded by children to take tablets, reported children to be 
good as reminders of adherence. 
 
3.16.8 ADHERENCE COUNSELLING AND PATIENT EDUCATION 
It is envisaged that the patient who knows their medication and their dosage have a high 
adherence rate. The education can be through graphics, verbal or written. The education on 
antiretroviral includes dietary restrictions, possible side effects and their management. The 
importance of maximum adherence to prevent the risk of virological failure is stressed during 
this phase (NCR, 2008). 
 
 
A study done in England with 116 participants, suggest that education improves adherence 
.The study assigned group of participants to intervention and control group. The intervention 
group received individualised education counselling at baseline and ongoing session’s .The 
information was provided on treatment adherence and resistance. The strategies of solving 
encountered challenges were discussed during ongoing counselling. The control group 
received standard of care clinical follow –up. 
 
The results at 48 weeks indicated a ≥ 95 % of adherence among 94% of the intervention 
group versus 645% of the control group. The viral load results of the 89% of the intervention 
group was < 400 copies/ml, as compared to 66% of the control group (Machtinger et al., 
2008). 
 
It is reported that antiretroviral adherence is maximised when the health care workers 
dedicate time with the patient to plan for and support medication adherence. 
 
According to the Standard operating procedure illustrated in Family Health International 
(FHI) (2004). The patient has to undergo three sessions of adherence counselling before 
starting with antiretroviral. The sessions include the information on HIV/AIDS, antiretroviral, 
resistance, importance of adherence, disclosure, reminders of adherence, healthy living and 
barriers to adherence. The prescribed tablets are discussed with the patient. A follow up 
session after starting antiretroviral is required. 
 
In trying to prevent failure among HIV/AIDDS infected adult initiating antiretroviral therapy 
Davies, Koenig, Stratford, Palmore, Bush, Golde, Melatino, Todd-Turner and Veller brock 
(2006) conducted a study at the infectious disease programme of Grady Health System in 
Atlanta, whereby the so called HEART project was implemented among HIV positive who 
were eligible for antiretroviral. 
 
HEART is the abbreviation of Helping Enhance Adherence to Retroviral Therapy. The 
HEART was implemented before the initiation of the therapy. The HEART involves two 
sessions of counselling before initiating therapy and other three sessions during the course of 
the therapy. During the first session clients are educated on HIV and therapy.HIV resistance 
is explained. It is ensured that before living the session, the clients know what is resistance 
(Davies et al., 2006). 
 
 
The second session is about assessment of the clients’ life style, in order to intergrate the life 
style with the therapy. The other three sessions are during the course of the therapy. The 
clinical nurse discusses the barriers to adherence with the clients. After discussion of the 
barrier, the plan is to make to help the patient adhere. The clients are seen as responsible for 
their own health, the relationship is not authoritarian. At the same time the clients are 
respected and receive autonomy support (Davies et al., 2006). 
 
According to Davies et al. (2006), the HEART project involves the use of support partners. 
Before the participants are initiated on treatment they are requested to bring the support 
partner, 90% of the participants were able to find the support partners; only 24 reported not 
finding the partner. Support partners are one of the underutilized resources in adherence 
counselling. Their function is to support the clients in reminding them about medication 
taking, either by telephone calls and help with reminders as the alarms. They can also collect 
the clients’ medication; in cases the clients are unable to do that for that day. The other role 
of the support partners is motivational. 
 
The support partners are encouraged to attend, at least one of the first two sessions and two of 
the four sessions. In our study those sessions were attended especially the first sessions. The 
HEART project also had six group meeting, which was coordinated by the HIV positive peer 
advocates. The intervention group were required to attend at least two of the sessions (Davies 
et al., 2006). 
 
The HEART project is informed by problem solving theory, self determination theory and 
cognitive research on prospective memory. Experience on adherence and clinical were 
integrated into this intervention. The HEART project according to the study has proven to be 
effective (Davies et al., 2006). 
 
Stenson, Charalambous, Dwadwa, Pemba, Du Toit, Raggaley, Grant and Churchyard (2005) 
conducted a study in one of the mines in South Africa to determine the understanding of the 
patient on ART’s, and the perception of the patient Health professionals on counselling 
process. 
 
The counselling included three steps. The first step which is the preparation for the ART, 
introduction to antiretroviral, risk, benefits and social ramification. The second step which 
 
 
was prior to starting antiretroviral reassessed knowledge and discussed patient‘s decision on 
whether to start. The third step, which was after starting antiretroviral, addressed progress and 
problems encountered (Stenson et al., 2005). 
 
90 % of the respondents scored 6/7 on the adherence questioners, 100% reported taking 
medication on daily basis.88% has knowledge of the regimen and doses. There is a need to 
equip the patient with information in order for them to adhere to antiretroviral and to 
empower them to care for their lives (Stenson et al., 2005).  
 
According to NRC (2008) patient education should encourage the patient to take the 
medication as prescribed, the importance of taking all the medication to attain maximum viral 
suppression and avoidance of the risk of developing drug resistance, encourage the clients to 
notify the clinic if they miss their doses, discuss the ways to improve adherence and 
adherence support, educate the patient on side effects, the reporting of the side effects and the 
way to reduce the side effects.  
 
It is very important during the adherence counselling that patient adherence strategies are  
emphasised, which are the keeping of appointment, the reporting of the side effects, the 
acceptance of the HIV/AIDS status, the acceptance that antiretro viral are lifelong treatment, 
realistic expectation of antiretroviral, belief in the benefits of antiretroviral, joining of support 
groups and religious organization for support, disclosing ,the use of reminders as discussed 
above, the importance of not mixing antiretroviral with any other medications, without 
consulting the doctor. 
 
3.16.9 INTERVENTION DURING ADHERENCE COUNSELLING 
The health care provider helps the client, to acquire, information, attitudes, skills and 
behaviour to ensure adherence. The health care provider set objectives, prioritise, limit 
objectives to be tackled with each intervention. The readiness to change is addressed. It is 
important that the comprehension and understanding is assessed. 
 
Instructional Strategy 
Information is effective if it is provided according to the need of the patient. The verbal 
communication which increases understanding are used for example, the health care provider 
need to be clear, concise, and explicit, categorise, and repeat important context, use of 
 
 
dialogue, test understanding and comprehension.  Written instruction and educational 
material are given (Fomundam, 2008). 
 
Behavioural Strategies. 
To ensure that the patient adopt and maintain health behaviour, the health provider develop 
the management plan. The patient is encouraged to monitor him/herself. The clients are 
informed on the clinical improvement. The treatment regimen is simplified. The family and 
friends care is integrated in the process of support (Fomundam, 2008). 
 
Motivational and Empowerment Strategies. 
It is envisaged that adherence tends to decrease towards baseline and with the cessation of 
intervention. The approach to motivate and empower the clients are as follows: Help the 
clients to adopt new approach, belief attitude and value. In appropriate beliefs that are 
congruent to the expected belief are pointed out. Increase knowledge were appropriate 
.Motivate the patient according to their value system. Encourage in times of failure. Involve 
the patient in the development of the management plans and the setting of the goals. Help the 
patient take credit for the good outcome. Facilitate problem solving and self monitoring 
(Fomundam, 2008). 
 
To ensure that the patient keeps appointment, negotiate the appointment time and interval 
with the patient. During referral, explain about the referral .The specifying of the names of 
the health professionals, the clients are referred to encourage keeping of appointment. The 
waiting period during the visit is to be shortened. Reminders, phone calls, community health 
workers can remind the clients of the appointment (Fomundam, 2008). 
 
3.16.10 MEASURING ADHERENCE 
There are several measures used to measure adherence which are ,Medication Event 
Monitoring System, Pill Count, Biological markers, assay, medication refill refill data ,Self 
Report as Morisky Scale, Visual Scale Analogue, CPCRA measures, the last three days recall 
method, and Direct Observed Treatment(DOT). 
 
Bell, Kapitao, Sikwese & Lallo (2007) used pill count; self reported adherence and 
Medication Events Monitoring System in measuring adherence. The pill count was calculated 
 
 
as follows:  tablets dispensed minus tablets returned divide by tablets prescribed, multiply by 
hundred. 
 
MEMS record the time of the container opening. It uses computer chip embedded in a pill 
bottle cap .The calculation is as follows, the number of bottle opening events divided by the 
prescribed number of doses multiply by 100. In cases where the number of the opening 
events was more than the prescribed dose, the data was adjusted so that the opening events 
equals to the prescribed doses in a day. An opening events repeated within four hours was 
taken as single events. 
 
Both Pill Count and Medication Events Monitoring System can over estimates and 
underestimates adherence. For example the clients may remove pills from the container 
before pill count. With MEMS the clients may open the container take the tablets out, but not 
drink the tablets. MEMS my undermine adherence, in cases where the clients may take 
several tablets out for other days or to the other small containers. 
 
According to Machtinger et al. (2008) self report is another method of assessing adherence. It 
is very effective when it is used by a neutral person who is not a member of the clinical staff 
member. Clients tend to tell the truth about their adherence behaviour, if they are in a 
comfortable environment and trusting the interviewer.  
 
The disadvantage with this method is that clients can lie about adhering to antiretroviral. 
Studies report that self report of good adherence has a limited value as a predictor of 
adherence, while self report of poor adherence is regarded as a predictor of poor adherence. 
Clients may self report being adherent in a fear of being labelled as disobedience   (NCR, 
2008). 
 
The China AIDS Response (CARES) study which‘s purpose was to describe the prevalence 
of adherence in China, to identify factors associated with adherence and to compare self 
report measures of adherence used CPRA adherence self report measures, a 7 day visual 
analogue scale (VAS). With VAS the participants were required to mark on the 10 cm line, 
which was labelled 0% to 100% in 10 interval, 0% indicates the clients are not taking 
medication at all, 50% indicate the clients are taking half of the medication and 100% 
 
 
indicate the client is taking all the medication. Wang, He, Li, .Yang, Chen, Fenni, Williams 
(2008). 
 
The study ,which ‘s aim was to test the validity, sensitivity and specificity of the pill count 
methods with respect to viral load measurement  and to explore other factors threatening high 
treatment adherence level was conducted in Mozambique ‘ DREAM programme(Drug 
Resource Enhancement  against AIDS and Malnutrition. Pill count in the study was done on 
the participants > 15 years, receiving first line antiretroviral therapy. The participants were 
observed for 12 months Lio, Carbini, Germano, Guidotti, Mancinelli, Magid, Narciso, 
Palombi, Renzi, Zimba &Marazzi (2008).  
 
 In measuring adherence Kouanfack, Laurent , Peytavin , Ciaffi, Ngolle, Nkene, Essomba , 
Calmy , Ngole , Delaporte, Koulla- Shiro (2008) used self report and nevirapine Plasma 
Level Concentration(biological marker). The nevirapine minimal plasma concentration was 
measured 12 hours after the last intake. This was done after every 6 months till months 36 for 
every patient receiving the FDC of nevirapine. A concentration of 4000 ng/ml, was judged as 
accurate adherence. The nevirapine  minimal plasma concentration was measured using 
validated reverse –phase high performance liquid  chromatographycoupled with ultraviolet 
detection assay, while plasma HIV-1VIRAL load was determined using Bayer branched 
DNA (BDNA) HIV -1 Quantiplex assay (Bayer Diagnostic Emeryville, CA) version 3.0 ( 
Limit of quantification of 50 copies/ml). 
 
The medication refill method can be used to measure adherence. Pharmacist dispenses 
medication for a particular period and the dates for the next appointment are always given. In 
cases where the refills are not obtained in timely fashion, it is assumed that the patient may 
not be adhering to antiretroviral (Machtiner et al., 2008). 
 
Direct Observed Treatment (DOT) 
According to Fomundam (2008) the clients while she/he is observed. The observation may be 
done by the health care workers. Many patients are not comfortable with this method, as 
soma feels it takes control from them. The method seems to violate patient’s autonomy and 
privacy. 
 
 
 
 
Other methods 
Another method illustrated by Fomundam (2008) is assays, assays measure drug level in 
blood, urine, breath, or saliva in measuring adherence to antiretroviral. The patient outcomes 
can be used to measure adherence. The improvement in the CD 4 count and the suppressed 
viral load may suggest adherence to antiretroviral.  
 
3.17 COUNSELLING 
Jacob John as cited in Saloner (2005) describes counselling as the communication that 
requires person to person conversation, with one of the key roles of the counsellor, being to 
listen to the patient uninteruptly during the appointment time.  
 
Saloner (2005) report that during counselling the clients is able to be open ,shares his 
emotions, fears, quilt and anxieties. In short counselling can be defined as a way of enabling 
clients to recognise, accept and resolve problems. Counselling can be done by health workers, 
social worker, psychologist and trained lay counsellors. Counselling can be done to provide 
information during pre and post counselling, when a counsellor identify a problem and when 
the clients report to have problems. 
 
Skills of a Counsellor 
According to Killian (2009) empathy, listening, reflecting, attentive behaviour,, reflecting 
feeling, questioning, summarising and problem solving. The counsellor also needs to create a 
safe space and always introduce herself. In dealing with the clients, the helper needs to create 
an environment which will encourage communication. The setting must have privacy and no 
interruption. The counsellor need to adopt caring attitudes, smile, shake hands with the clients 
and introduce herself to the clients. 
 
Empathy 
This is trying to understand what the clients are going through. It is very important to be non 
judgmental and understand what the clients is feeling (Kallian, 2009). 
 
Listening 
Listening means hearing and understanding what the clients is saying .It is very important to 
pay attention to what it is said. Listening includes listening and encouraging the clients 
through verbal and non verbal communication (Kallian, 2009). 
 
 
Reflection 
According to Kallian (2009) reflection involves developing the picture of what the clients is 
feeling and experiencing. During reflection what is understood is communicated to the clients 
to check, whether it is correct.  
 
Attentive behaviour 
According to Kallian (2009) attentive behaviour suggest to the clients whether she is listened 
or not. The important attentive behaviour is eye contact, attentive body language as 
encouraging gestures, vocal qualities and verbal track.  
 
Questioning 
In counselling questioning is necessary for the clients to open up. Open ended questions 
allow the clients to give expanded response. The counsellor in the process gets more 
information from the clients (Kallian, 2009). 
 
Summarising 
According to Kallian (2009) summarising is connecting experiences, feeling, behaviour and 
subsequent events. The helper must check if the clients agree with the summary. It is very 
appropriate to summarise when moving to a new topic, or at the end of the session. 
 
Problem solving 
The clients is encouraged to take responsibility of the problem and encouraged through the 
various steps in solving the problem, as understanding the problem, setting goals, 
brainstorming, identifying pros and cons of the brainstormed option and the take action. The 
taken action is then evaluated and followed by future plans in the next session (Kallian, 
2009). 
 
Robert Carkhuff as cited in Saloner (2005) explores steps in counselling as attending, 
responding, and personalizing. Attending refers to prompting the clients’ own attentiveness. 
Responding means responding to the content and the meaning. Personalising is to enable the 
clients to understand where he/she is in relation to where he wants to be.  
 
The counsellor according to David Muller as cited in Saloner (2005) has to be able to have 
confidentiality, to always be accessible, have a non-judgmental perspective and a consistency 
 
 
in approach to the individual. Counsellors need to be trained in order to meet these 
requirements (Saloner, 2005). 
 
3.18 PRE AND POST TEST COUNSELLING 
HIV counselling is the giving of information to the clients regarding  HIV/AIDS, in order to 
assist them to make an informed decision as far as  HIV/AIDS testing is concerned.HIV 
counselling into divided  pre -counselling and post- counselling  testing. 
 
Pre –Counselling Test 
This is the type of counselling where the clients is prepared for the HIV test and its outcomes. 
The clients are informed on the pros and cons of HIV/ AIDS counselling. The basic 
information on HIV is provided to the clients. That is the information on what is HIV/AIDS, 
the mode of transmission, the preventative strategies and the available support services. 
According to Saloner (2005) the information given to the clients will depend on the 
background information that the clients already have. 
 
The HIV counselling explores the content of the HIV test. Clients are given information on 
the HIV test, and the clients are allowed to ask questions. The implication of the test is 
discussed with the client.  
 
Saloner (2005) in her work explains the many implication the HIV status may have on the 
individuals. The example of this implication is the psychosocial and financial implication 
.The Risk assessment is done. The clients’ possible risk of contracting HIV/AIDS is assessed. 
The information on healthy life styles is given to avoid the risk of contracting the disease. 
The clients are assured. It is very important to enquire from the clients on what will he do if 
she find out of their HIV status.  
 
AfA (2004) report that the clients need to be assured on the confidentiality of the test results, 
and the test results will not be disclosed to the other parties without the client’s consent. The 
DOH (1999) in their draft of National HIV/AIDS policy indicated several conditions in 
which HIV/AIDS testing should be carried out, with the consent from the clients and without 
consent from the clients. The clients have to issue the consent in a situation “devoid of 
coercion”. The client must feel free to refuse and agree for HIV test. 
 
 
 
Post - Test Counselling 
During post – test counselling the client is given the results of the test and assured depending 
on the results. Post –counselling is done irrespective of the negative and positive results. 
Saloner (2005) report that the service provider in giving the results need to be calm and 
professional. In cases of the HIV positive results the service provider need to support and 
provide to the clients information on the available services and help the clients can receive. 
For the antiretroviral programme available and other services which may be of assistance to 
the clients. 
 
In dealing with the clients during this counselling session the provider of service should 
expect different emotion from the clients as anger, fear, shock, denial. It is very appropriate 
that the clients is allowed to express his emotions Saloner (2005). 
 
There is a lot of stigma attached to HIV/AIDS; in that case it may not be an easy step for the 
clients to accept their HIV/AIDS status. The service provider ‘s role in this case is to assure 
the clients and try to clarify whatever concerns and misconception the clients is having on 
HIV/AIDS. Care must be taken not to give false hopes to the clients. 
 
The feeling of the clients in regards to his status, either negative or positive need to be 
discussed. Information on the preventive strategies and life style changes need to be 
emphasized. The post –counselling is to be followed by an ongoing counselling, to assess 
how the clients are coping and address other clients concerns. Ongoing counselling sessions 
will depend on the individual patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 4. ANALYSIS OF DATA AND THE DISCUSSION OF FINDINGS 
 
4.1 DEMOGRAPHIC DATA 
Figure 7. Illustration of Demographic Variables 
 
VARIABLES  N51 (%) 
 AGE 
15-49 
>49 
GENDER 
MALE 
FEMALE 
MARITAL STATUS 
SINGLE 
MARRIED 
DIVORCED 
COHABITING 
ENGAGED 
LITERACY LEVEL 
NEVER ATTENDED SCHOOL 
PRIMARY EDUCATION 
SECONDARY EDUCATION 
TERTIARY EDUCATION 
EMPLOYMENT STATUS 
UNEMPLOYED 
PENSIONER 
GOVERNMENT GRANT 
EMPLOYED 
RETRENCHED 
NO RESPONSE 
RESIDENTIAL AREA 
 
44(86, 6%) 
7(13, 7%) 
 
14(27, 5%) 
37(72, 5%) 
 
26(51, 0%) 
13(25, 5%) 
6(11, 8%) 
6(11, 8%) 
0(0, 0%) 
 
3(5, 9%) 
6(11, 8%) 
25(49, 0%) 
17(33, 3%) 
 
22(43, 1%) 
0(0, 0%) 
0(0, 0%) 
28(54, 9%) 
0(0, 0%) 
1(2, 0%) 
 
 
 
TOWNSHIP 
SURBURB 
TOWNSHIP / SURBURB 
INFORMAL SETTLEMENT 
OTHER 
NO RESPONSE 
DISCLOSER 
FAMILY 
FRIENDS 
COLLEAGUE 
SATISFACTION WITH SUPPORT 
FROM 
HEALTH PROFESSIONALS 
FAMILY 
FRIENDS 
COLLEAGUE 
ALCOHOL CONSUMPTION 
YES 
NO 
OCCASIONAL 
NO RESPONSE 
DRUG USE 
YES 
NO 
LENGTH OF TREATMENT IN 
MONTHS 
6 months or less 
>6 months - 12 months 
>12 months - 24 months 
>24 months - 36 months 
>36 months  
No response 
NUMBER OF PILLS A DAY 
24(47, 1%) 
6(11, 8%) 
15(29, 4%) 
0(0, 0%) 
5(9, 8%) 
1(2, 0%) 
 
48(94, 1%) 
22(43, 1%) 
3(5, 9%) 
 
41(80, 4%) 
49(96, 1%) 
17(33, 3%) 
3(5, 9%) 
 
2(3, 9%) 
37(72, 5%) 
11(21, 6%) 
1(2, 0%) 
 
0(0, 0%) 
51(100, 0%) 
 
0(0, 0%) 
21(41, 2%) 
17(33, 3%) 
5(9, 8%) 
7(13, 7%) 
1(2, 0%) 
 
0(0, 0%) 
0(0, 0%) 
 
 
1 PILL 
2 PILLS 
3 PILLS 
4 PILLS 
5 PILLS 
6 PILLS 
7 PILLS 
8 PILLS 
2(3, 9%) 
2(3, 9%) 
24(47, 1%) 
20(39, 2%) 
0(0, 0%) 
3(5, 9%) 
 
Age 
Forty four (86, 6%) patients were from the age of 15 to 49 year old and seven (13, 7%) of the 
patients were over 49 years old. 
 
Gender 
Fourteen (27, 5%) patients were male and thirty seven (72, 5%) were female. 
 
Marital status 
Twenty six (51, 0%) patients were single, married (13 or 25, 5%), divorced (6 or 11, 8%) and 
cohabiting (6 or 11, 8%). 
 
Literacy level 
Three (5, 9%) never attended school, primary education (6 or 11, 8%), secondary education 
(25 or 49, 0%) and tertiary education (17 or 33, 3%). 
 
Employment status 
Twenty two (43, 1%) were unemployed, Twenty eight (54, 9%) were employed and one (2, 
0%) did not indicate their employment status. 
 
Residential area 
Twenty four (47, 1%) of the patients were living in a township, suburb (6 or 11, 8%), 
township / suburb (15 or 29, 4%), other (5 or 9, 8%) and one (2, 0%) did not give an answer 
as to where he/she lives. 
 
 
 
 
Discloser 
Forty eight (94, 1%) disclosed to their family, 22 (43, 1%) to friends and 3 (5, 9%) to 
colleague. 
 
Satisfaction with support from 
Forty one (80, 4%) were satisfied with the support from health professionals, 49 (96, 1%) 
were satisfied with the support from the family, 17 (33, 3%) were satisfied with the support 
from friends and 3 (5, 9%) were satisfied with the support from colleagues. 
 
Alcohol Consumption 
Of the fifty one patients interviewed, two (3, 9%) of the patients interviewed said they 
consume alcohol, thirty seven (72, 5%) said they don’t consumer alcohol, eleven (21, 6%) 
said they drink occasionally and one (2, 0%) patient did not respond to the question. 
 
Drug Use 
All the respondents said they do not use drugs. 
 
Length of treatment in months 
No patient had a treatment for 6 months or less, twenty one (41, 2%) were in treatment for 
more than 6 months to 12 months, seventeen (33, 3%) were in treatment for more than 12 
months to 24 months, five (9, 8%) were in treatment for more than 36 months and one (2, 
0%) did not respond. 
 
Number of Pills a day 
Two patients (3,9%) drank 3 pills,  the other  two (3,9%) drank 4 pills, twenty four (47,1%) 
drank 5 pills, twenty  (39,2%) drank 6 pills, and three (5,9%) drank 8 pills. 
 
4.2 PILLS TYPES 
 
Figure 8. Type of Pills taken by the Patient 
 
 
 
 
 
 
 
Eight (15, 7%) patients were taking Lazed, EFV (25 or 49, 0%), AZT (8 or 15, 7%), 3TC (43 
or 84, 3%), d4T (36 or 70, 6%), NVP (22 or 43, 1%), Alluvia (3 or 5, 9%) and TDF (1 or 2, 
0%). 
 
4.3 REGIMEN TYPE 
 
Figure 9.  Regimen Types 
 
 
 
 
Eighteen (35, 3%) patients were taking regimen 1A, regimen 1B (16 or 31, 4%), regimen 2 (0 
or 0, 0%), regimen 2(Reviewed) (4 or 7, 8%), mixed regimen (12 or 23, 5%) and other 
regimen (1 or 2, 0%). 
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2.6.4 PILL COUNT METHOD ANALYSIS 
 
Figure 10.  Analysis of Pill Count 
 
 
 
 
 
One (2%) patient had 70% adherence, 2 (3,9%) had 86% adherence, 2 (3,9%) had 89% 
adherence, 1 (2,0%) had 91% adherence, 2 (3,9%) had 93% adherence, 2 (3,9%) had 95% 
adherence, 1 (2,0%) had 96% adherence, 1 (2,0%) had 97% adherence, 2 (3,9%) had 99% 
adherence, 36 (70,6%) had 100% adherence and 1 (2,0%) did not respond.  
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Overall, 42 patients had the adherence of more or equals to 95%, 8 patients had adherence of 
less than 95% and 1 did not respond. 
 
Age 
Of the 44 patients of the age 15 to 49, 38 had the adherence of more or equals 95%, 5 had the 
adherence of less than 95% and 1 did not respond. 
Of the 7 patients of the age above 49, 4 had the adherence of more or equals 95% and 3 had 
the adherence of less than 95%. 
 
Gender 
Of the 14 patients who were male, 10 had the adherence of more or equals 95% and 4 had the 
adherence of less than 95%. 
Of the 37 patients who were female, 32 had the adherence of more or equals 95%, 4 had the 
adherence of less than 95% and 1 did not respond. 
 
Marital status 
Of the 26 patients who were single, 20 had the adherence of more or equals 95% and 6 had 
the adherence of less than 95%. 
Of the 13 patients who were married, 11 had the adherence of more or equals 95%, 1 had the 
adherence of less than 95% and 1 did not respond. 
All the 6 divorced patients had the adherence of more or equal 95%. 
Of the 6 patients who were cohabiting, 5 had the adherence of more or equals 95% and 1 had 
the adherence of less than 95%. 
 
Literacy level 
Of the 3 patients who never attended school, 1 had the adherence of more or equals 95% and 
2 had the adherence of less than 95%. 
Of the 6 patients who had primary education, 5 had the adherence of more or equals 95% and 
1 had the adherence of less than 95%. 
Of the 25 patients who had secondary education, 20 had the adherence of more or equals 
95%, 4 had the adherence of less than 95% and 1 did not respond. 
Of the 17 patients who had tertiary education, 16 had the adherence of more or equals 95% 
and 1 had the adherence of less than 95%. 
 
 
 
Employment status 
Of the 22 patients who were unemployed, 20 had the adherence of more or equals 95%, 1 had 
the adherence of less than 95% and 1 did not respond. 
Of the 28 patients who were employed, 21 had the adherence of more or equals 95% and 7 
had the adherence of less than 95%. 
The only patient who did not respond to the employment status had the adherence more or 
equals 95%. 
 
Residential area 
Of the 24 patients who were living in township, 19 had the adherence of more or equals 95% 
and 5 had the adherence of less than 95%. 
All the 6 patients who were living in suburb had the adherence more or equal 95%. 
Of the 15 patients who were living in township/suburb, 12 had the adherence of more or 
equals 95%, 2 had the adherence of less than 95% and 1 did not respond. 
Of the 5 patients who were living at other residential area, 4 had the adherence of more or 
equals 95% and 1 had the adherence of less than 95%. 
The only patient who did not respond to the residential area had the adherence more or equal 
95%. 
 
Discloser 
Of the 48 patients said the disclosed to family, 39 had the adherence of more or equals 95%, 
8 had the adherence of less than 95% and 1 did not respond. 
Of the 22 patients said the disclosed to friends, 20 had the adherence of more or equals 95% 
and 2 had the adherence of less than 95%. 
All the 3 patients said the disclosed the colleague had the adherence more or equal 95%. 
 
Satisfaction with support from 
Of the 41 patients who said they were satisfied with the support from health professional, 34 
had the adherence of more or equals 95%, 6 had the adherence of less than 95% and 1 did not 
respond. 
Of the 49 patients who said they were satisfied with the support from family, 40 had the 
adherence of more or equals 95%, 8 had the adherence of less than 95% and 1 did not 
respond. 
 
 
Of the 17 patients who said they were satisfied with the support from friends, 15 had the 
adherence of more or equals 95% and 2 had the adherence of less than 95%. 
All the 3 patients who said they were satisfied with the support from colleague had the 
adherence more or equal 95%. 
 
Alcohol Consumption 
All the 2 patients who said they consume alcohol had the adherence more or equal 95%. 
Of the 37 patients who said they do not consume alcohol, 30 had the adherence of more or 
equals 95%, 6 had the adherence of less than 95% and 1 did not respond. 
Of the 11 patients who said they consume alcohol occasionally, 9 had the adherence of more 
or equals 95% and 2 had the adherence of less than 95%. 
The only patient who did not respond to the alcohol consumption had the adherence more or 
equal 95%. 
 
Drug Use 
All the 51 patients said they do not use drugs, 42 had the adherence of more or equals 95%, 8 
had the adherence of less than 95% and 1 did not respond. 
 
Length of treatment in months 
Of the 21 patients who had treatment for more than 6 months to 12 months, 19 had the 
adherence of more or equals 95% and 3 had the adherence of less than 95%. 
Of the 17 patients who had treatment for more than 12 months to 24 months, 12 had the 
adherence of more or equals 95%, 4 had the adherence of less than 95% and 1 did not 
respond. 
All of the 5 patients who had treatment for more than 24 months to 36 months had the 
adherence of more or equals 95%. 
Of the 7 patients who had treatment for more than 36 months, 6 had the adherence of more or 
equals 95% and 1 had the adherence of less than 95%. 
The only patient who did not respond to the length of treatment had the adherence of more or 
equal 95%. 
 
Number of Pills a day 
All the 2 patients who took 3 pills had the adherence of more or equal 95%. 
All the 2 patients who took 4 pills had the adherence of more or equal 95%. 
 
 
Of the 24 patients who took 5 pills, 18 had the adherence of more or equals 95%, 5 had the 
adherence of less than 95% and 1 did not respond. 
Of the 20 patients who took 6 pills, 18 had the adherence of more or equals 95% and 2 had 
the adherence of less than 95%. 
Of the 3 patients who took 8 pills, 2 had the adherence of more or equals 95% and 1 had the 
adherence of less than 95%. 
 
Regimen type 
Of the 18 patients who took regimen 1A, 13 had the adherence of more or equals 95%, 4 had 
the adherence of less than 95% and 1 did not respond. 
Of the 16 patients who took regimen 1B, 13 had the adherence of more or equals 95% and 3 
had the adherence of less than 95%. 
All the 4 patients who took regimen 2 (reviewed) had the adherence of more or equal 95%. 
Of the 12 patients who took mixed regimen, 11 had the adherence of more or equals 95% and 
1 had the adherence of less than 95%. 
The only patient who took other regimen had the adherence of more or equals 95%. 
 
Type of pills taken by patient 
All the 8 patients who took Lamzid had the adherence of more or equal 95%. 
Of the 25 patients who took EFV, 20 had the adherence of more or equals 95%, 4 had the 
adherence of less than 95% and 1 did not respond. 
Of the 8 patients who took AZT, 7 had the adherence of more or equals 95% and 1 had the 
adherence of less than 95%. 
Of the 43 patients who took 3TC, 34 had the adherence of more or equals 95%, 8 had the 
adherence of less than 95% and 1 did not respond. 
Of the 36 patients who took d4T, 27 had the adherence of more or equals 95%, 8 had the 
adherence of less than 95% and 1 did not respond. 
Of the 22 patients who took NVP, 19 had the adherence of more or equals 95% and 3 had the 
adherence of less than 95%.  
All the 3 patients who took Alluvia had the adherence of more or equal 95%. 
The only patient who took TDF had the adherence of more or equals 95%. 
 
Figure 12.  All Percentage of Pill Count in Relation to Demographics 
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Age 
Of the 44 patients of the age 15 to 49, 2 had 86% adherence, 1 had 89% adherence, 1 had 
91% adherence, 1 had 93% adherence, 2 had 95% adherence, 1 had 96% adherence, 2 had 
99% adherence, 33 had 100% adherence and 1 did not respond. 
Of the 7 patients of the age above 49, 1 had 70% adherence, 1 had 89% adherence, 1 had 
93% adherence, 1 had 97% adherence and 3 had 100% adherence. 
 
Gender 
Of the 14 patients who were male, 1 had 70% adherence, 1 had 86% adherence, 2 had 89% 
adherence, 1 had 97% adherence, 2 had 99% adherence and 7 had 100% adherence. 
Of the 37 patients who were female, 1 had 86% adherence, 1 had 91% adherence, 2 had 93% 
adherence, 2 had 95% adherence, 1 had 96% adherence, 29 had 100% adherence and 1 did 
not respond. 
 
Marital status 
Of the 26 patients who were single, 1 had 70% adherence, 2 had 86% adherence, 1 had 89% 
adherence, 2 had 93% adherence, 1 had 96% adherence, 1 had 97% adherence and 18 had 
100% adherence. 
Of the 13 patients who were married, 1 had 89% adherence, 2 had 99% adherence, 9 had 
100% adherence and 1 did not respond. 
All 6 the divorced patients had 100% adherence. 
Of the 6 patients who were cohabiting, 1 had 91% adherence, 2 had 95% adherence and 3 had 
100% adherence. 
 
 
Literacy level 
Of the 3 patients who never attended school, 1 had 70% adherence, 1 had 93% adherence and 
1 had 100% adherence. 
Of the 6 patients who had primary education, 1 had 91% adherence, 2 had 95% adherence 
and 3 had 100% adherence. 
Of the 25 patients who had secondary education, 2 had 86% adherence, 2 had 89% 
adherence, 1 had 96% adherence, 1 had 97% adherence, 1 had 99% adherence, 17 had 100% 
adherence and 1 did not respond. 
Of the 17 patients who had tertiary education, 1 had 93% adherence, 1 had 99% adherence 
and 15 had 100% adherence. 
 
Employment status 
Of the 22 patients who were unemployed, 1 had 86% adherence, 1 had 96% adherence, 1 had 
97% adherence, 1 had 99% adherence, 17 had 100% adherence and 1 did not respond. 
Of the 28 patients who were employed, 1 had 70% adherence, 1 had 86% adherence, 2 had 
89% adherence, 1 had 91% adherence, 2 had 93% adherence, 2 had 95% adherence, 1 had 
99% adherence and 18 had 100% adherence. 
The only patient who did not respond to the employment status had the adherence of 100%. 
 
Residential area 
Of the 24 patients who were living in township, 2 had 86% adherence, 2 had 89% adherence, 
1 had 93% adherence, 1 had 95% adherence, 1 had 96% adherence, 1 had 97% adherence, 2 
had 99% adherence and 14 had 100% adherence. 
All 6 patients who were living in suburb had 100% adherence. 
Of the 15 patients who were living in township/suburb, 1 had 70% adherence, 1 had 93% 
adherence, 1 had 95% adherence, 11 had 100% adherence and 1 did not respond. 
Of the 5 patients who were living at other residential area, 1 had 91 and 4 had 100% 
adherence. 
The only patient who did not respond to the residential area had the adherence of 100%. 
 
Discloser 
Of the 48 patients said the disclosed to family, 1 had 70% adherence, 2 had 86% adherence, 2 
had 89% adherence, 1 had 91% adherence, 2 had 93% adherence, 2 had 95% adherence, 1 
had 97% adherence, 2 had 99% adherence, 34 had 100% adherence and 1 did not respond. 
 
 
Of the 22 patients said the disclosed to friends, 1 had 86% adherence, 1 had 93% adherence, 
1 had 96% adherence, 1 had 99% and 18 had 100% adherence. 
All the 3 patients said the disclosed the colleague had the adherence of 100%. 
 
Satisfaction with support from 
Of the 41 patients who said they were satisfied with the support from health professional, 1 
had 70% adherence, 2 had 86% adherence, 2 had 89% adherence, 1 had 93% adherence, 2 
had 95% adherence, 1 had 97% adherence, 2 had 99% adherence, 29 had 100% adherence 
and 1 did not respond. 
Of the 49 patients who said they were satisfied with the support from family, 1 had 70% 
adherence, 2 had 86% adherence, 2 had 89% adherence, 1 had 91% adherence, 2 had 93% 
adherence, 2 had 95% adherence, 1 had 96% adherence, 1 had 97% adherence, 2 had 99% 
adherence, 34 had 100% adherence and 1 did not respond. 
Of the 17 patients who said they were satisfied with the support from friends, 1 had 86% 
adherence, 1 had 93% adherence, 1 had 99% adherence and 14 had 100% adherence. 
All the 3 patients who said they were satisfied with the support from colleague had the 
adherence of 100%. 
 
Alcohol Consumption 
Of the 2 patients who said they consume alcohol, 1 had 99% adherence and 1 had 100% 
adherence. 
Of the 37 patients who said they do not consume alcohol, 2 had 86% adherence, 1 had 89% 
adherence, 1 had 91% adherence, 2 had 93% adherence, 1 had 95% adherence, 1 had 97% 
adherence, 1 had 99% adherence, 27 had 100% adherence and 1 did not respond. 
Of the 11 patients who said they consume alcohol occasionally, 1 had 70% adherence, 1 had 
89% adherence, 1 had 95% adherence, 1 had 96% adherence and 7 had 100% adherence. 
The only patient who did not respond to the alcohol consumption had the adherence of 100%. 
 
Drug Use 
All the 51 patients said they do not use drugs, 1 had 70% adherence, 2 had 86% adherence, 2 
had 89% adherence, 1 had 91% adherence, 2 had 93% adherence, 2 had 95% adherence, 1 
had 96% adherence, 1 had 97% adherence, 2 had 99% adherence, 36 had 100% adherence 
and 1 did not respond. 
 
 
 
Length of treatment in months 
Of the 21 patients who had treatment for a year or less, 1 had 70% adherence, 1 had 86% 
adherence, 1 had 89% adherence, 1 had 95% adherence, 2 had 99% adherence and 15 had 
100% adherence. 
Of the 17 patients who had treatment for more than a year but less or equals to two years, 1 
had 86% adherence, 1 had 89% adherence, 1 had 91% adherence, 1 had 93% adherence, 1 
had 95% adherence, 1 had 96% adherence, 1 had 97% adherence, 9 had 100% adherence and 
1 did not respond. 
Of the 12 patients who had treatment for more than two years, 1 had 93% adherence and 11 
had 100% adherence. 
The only patient who did not respond to the length of treatment had the adherence of 100%. 
 
Number of Pills a day 
Of the 2 patients who took 3 pills, 1 had 95% adherence and 1 had 100% adherence. 
The 2 patients who took 4 pills had 100% adherence. 
Of the 24 patients who took 5 pills, 1 had 86% adherence, 2 had 89% adherence, 1 had 91% 
adherence, 1 had 93% adherence, 1 had 95% adherence, 1 had 97% adherence, 1 had 99% 
adherence, 15 had 100% adherence and 1 did not respond. 
Of the 20 patients who took 6 pills, 1 had 86% adherence, 1 had 93% adherence, 1 had 96% 
adherence, 1 had 99% adherence and 16 had 100% adherence. 
Of the 3 patients who took 8 pills, 1 had 70% adherence and 2 had 100% adherence 
 
4.5 LAST THREE DAYS RECALL METHOD ANALYSIS 
 
Figure 13. Analysis of Last Three Days Methods 
 
In the last three days did you take all your tablets as prescribed? 
 
YES NO 
50(98, 0%) 1(2, 0%) 
 
Fifty (98, 0%) patients said yes and only one (2, 0%) said no. 
 
 
 
4.6 MORISKY SCALE 
 
Figure 14.  Analysis of Moresby Scale 
 
 Never Rarely Sometimes Often Always 
1. Do you ever forget to 
take your medications? 
29 
56,9% 
18 
35,3% 
4 
7,8% 
0 
0,0% 
0 
0,0% 
2. Are sometimes 
careless about taking 
your medication? 
45 
88,2% 
3 
5,9% 
3 
5,9% 
0 
0,0% 
0 
0,0% 
3. When you feel better, 
do you sometimes stop 
taking your 
Medications? 
51 
100,0% 
0 
0,0% 
0 
0,0% 
0 
0,0% 
0 
0,0% 
4. Sometimes, if you 
feel worse when you 
take your medication, 
do you stop taking 
them? 
51 
100,0% 
0 
0,0% 
0 
0,0% 
0 
0,0% 
0 
0,0% 
 
1. Do you ever forget to take your medications? 
Four (7, 8%) patients said sometimes, eighteen (35, 3%) said rarely and twenty nine (56, 9%) 
said never. 
2. Are sometimes careless about taking your medication? 
Three (5, 9%) patients said sometimes, three (5, 9%) said rarely and forty five (88, 2%) said 
never. 
3. When you feel better, do you sometimes stop taking your Medications? 
All the patients said never. 
4. Sometimes, if you feel worse when you take your medication, do you stop taking them? 
All the patients said never. 
 
 
 
 
 
4.7 VISUAL ANALOGUE SCALE (VAS) 
 
Figure 15. Analysis of VAS 
 
 
 
On average 42 (82, 4%) of the patients had a 100% adherence, 7 (13, 7%) had 90% 
adherence, 1 (2, 0%) had 80% adherence and 1 (2, 0%) had 70% adherence. 
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Overall, 42 patients had the adherence of more or equals to 95% and 9 patients had adherence 
of less than 95%. 
 
Age 
Of the 44 patients of the age 15 to 49, 38 had the adherence of more or equals 95% and 6 had 
the adherence of less than 95%. 
Of the 7 patients of the age above 49, 4 had the adherence of more or equals 95% and 3 had 
the adherence of less than 95%. 
 
Gender 
Of the 14 patients who were male, 8 had the adherence of more or equals 95% and 6 had the 
adherence of less than 95%. 
Of the 37 patients who were female, 34 had the adherence of more or equals 95% and 3 had 
the adherence of less than 95%. 
 
Marital status 
Of the 26 patients who were single, 20 had the adherence of more or equals 95% and 6 had 
the adherence of less than 95%. 
Of the 13 patients who were married, 11 had the adherence of more or equals 95% and 2 had 
the adherence of less than 95%. 
Of the 6 patients who were divorced, 5 had the adherence of more or equals 95% and 1 had 
the adherence of less than 95%. 
All the 6 patients who were cohabiting had the adherence of more or equal 95%. 
 
Literacy level 
Of the 3 patients who never attended school, 1 had the adherence of more or equals 95% and 
2 had the adherence of less than 95%. 
All the 6 patients who had primary education had the adherence of more or equal 95%. 
Of the 25 patients who had secondary education, 18 had the adherence of more or equals 95% 
and 7 had the adherence of less than 95%. 
All the 17 patients who had tertiary education had the adherence of more or equal 95%. 
 
 
 
 
 
Employment status 
Of the 22 patients who were unemployed, 19 had the adherence of more or equals 95% and 3 
had the adherence of less than 95%. 
Of the 28 patients who were employed, 22 had the adherence of more or equals 95% and 6 
had the adherence of less than 95%. 
The only patient who did not respond to the employment status had the adherence more or 
equals 95%. 
 
Residential area 
Of the 24 patients who were living in township, 18 had the adherence of more or equals 95% 
and 6 had the adherence of less than 95%. 
All the 6 patients who were living in suburb had the adherence more or equal 95%. 
Of the 15 patients who were living in township/suburb, 13 had the adherence of more or 
equals 95% and 2 had the adherence of less than 95%. 
Of the 5 patients who were living at other residential area, 4 had the adherence of more or 
equals 95% and 1 had the adherence of less than 95%. 
The only patient who did not respond to the residential area had the adherence more or equal 
95%. 
 
Discloser 
Of the 48 patients said the disclosed to family, 39 had the adherence of more or equals 95% 
and 9 had the adherence of less than 95%. 
Of the 22 patients said the disclosed to friends, 18 had the adherence of more or equals 95% 
and 4 had the adherence of less than 95%. 
All the 3 patients said the disclosed the colleague had the adherence more or equal 95%. 
 
Satisfaction with support from 
Of the 41 patients who said they were satisfied with the support from health professional, 32 
had the adherence of more or equals 95% and 9 had the adherence of less than 95%. 
Of the 49 patients who said they were satisfied with the support from family, 40 had the 
adherence of more or equals 95% and 9 had the adherence of less than 95%? 
Of the 17 patients who said they were satisfied with the support from friends, 14 had the 
adherence of more or equals 95% and 3 had the adherence of less than 95%. 
 
 
All the 3 patients who said they were satisfied with the support from colleague had the 
adherence more or equal 95%. 
 
Alcohol Consumption 
All the 2 patients who said they consume alcohol had the adherence more or equal 95%. 
Of the 37 patients who said they do not consume alcohol, 31 had the adherence of more or 
equals 95% and 6 had the adherence of less than 95%. 
Of the 11 patients who said they consume alcohol occasionally, 8 had the adherence of more 
or equals 95% and 3 had the adherence of less than 95%. 
The only patient who did not respond to the alcohol consumption had the adherence more or 
equal 95%. 
 
Drug Use 
All the 51 patients said they do not use drugs, 42 had the adherence of more or equals 95% 
and 9 had the adherence of less than 95%. 
 
Length of treatment in months 
Of the 21 patients who had treatment for more than 6 months to 12 months, 16 had the 
adherence of more or equals 95% and 5 had the adherence of less than 95%. 
Of the 17 patients who had treatment for more than 12 months to 24 months, 14 had the 
adherence of more or equals 95%, 3 had the adherence of less than 95% and 1 did not 
respond. 
All of the 5 patients who had treatment for more than 24 months to 36 months had the 
adherence of more or equals 95%. 
Of the 7 patients who had treatment for more than 36 months, 6 had the adherence of more or 
equals 95% and 1 had the adherence of less than 95%. 
The only patient who did not respond to the length of treatment had the adherence of more or 
equal 95%. 
 
Number of Pills a day 
All the 2 patients who took 3 pills had the adherence of more or equal 95%. 
All the 2 patients who took 4 pills had the adherence of more or equal 95%. 
Of the 24 patients who took 5 pills, 18 had the adherence of more or equals 95% and 6 had 
the adherence of less than 95%. 
 
 
Of the 20 patients who took 6 pills, 18 had the adherence of more or equals 95% and 2 had 
the adherence of less than 95%. 
Of the 3 patients who took 8 pills, 2 had the adherence of more or equals 95% and 1 had the 
adherence of less than 95%. 
 
Regimen type 
Of the 18 patients who took regimen 1A, 12 had the adherence of more or equals 95% and 6 
had the adherence of less than 95%. 
Of the 16 patients who took regimen 1B, 13 had the adherence of more or equals 95% and 3 
had the adherence of less than 95%. 
All the 4 patients who took regimen 2 (reviewed) had the adherence of more or equal 95%. 
All the 12 patients who took mixed regimen had the adherence of more or equal 95%. 
The only patient who took other regimen had the adherence of more or equals 95%. 
 
Type of pills taken by patient 
All the 8 patients who took Lamzid had the adherence of more or equal 95%. 
Of the 25 patients who took EFV, 19 had the adherence of more or equals 95%, 6 had the 
adherence of less than 95% and 1 did not respond. 
All the 8 patients who took AZT had the adherence of more or equal 95%. 
Of the 43 patients who took 3TC, 34 had the adherence of more or equals 95% and 9 had the 
adherence of less than 95%. 
Of the 36 patients who took d4T, 27 had the adherence of more or equals 95% and 9 had the 
adherence of less than 95%. 
Of the 22 patients who took NVP, 19 had the adherence of more or equals 95% and 3 had the 
adherence of less than 95%. 
All the 3 patients who took Alluvia had the adherence of more or equal 95%. 
The only patient who took TDF had the adherence of more or equals 95% 
 
 
 
 
 
 
 
 
 
4.8 CD4 COUNT ANALYSIS 
 
 Figure 17.  CD4 Count  Results 
 
 > 200 CD4 
(Improved immunity 
and adherence) 
< 200 CD4 (risk to 
opportunistic 
infections and poor 
adherence) 
No Response 
Baseline CD 4 count 0 (0,0%) 50 (98,0%) 1 (2, 0%) 
Recent CD 4 count 34 (66, 7%) 17 (33, 3%) 0 (0, 0%) 
 
Fifty (98, 0%) patients had the CD4 count of less than 200 before taking the treatment and 1 
(2, 0%) did not respond to the question. 
After taking the treatment 34 (66, 7%) had the CD4 count of more than 200 and 17 (33, 3%) 
had the CD4 of less than 200.  
 
Figure 18. Comparison between Baseline and Recent CD4 Count 
 
 
 
 
 
 
All patients had the recent CD4 count that was more that the baseline CD4 counts except one. 
Respondent number 10 had the baseline CD4 count of 161 and the recent CD4 count of 146. 
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2.6.9 VIRAL LOAD ANALYSIS 
 
Figure 19. VIRAL LOAD (VL) RESULTS (Recent) 
 
< 25 RNA Copies /ml 34 (66, 7%) 
> 25 and <400 RNA Copies /ml 11 (21, 6%) 
400 to 5000 Copies/ml 4 (7, 8%) 
>5000 Copies/ml 1 (2, 0%) 
No response 1 (2, 0%) 
 
Thirty four (66,7%) patients had a viral load that was below the detectable level (i.e. 25 RNA 
Copies/ml), 11 (21,6%) had viral load that was below 400 RNA Copies/ml, 1 (2,0%) had 
viral load that was above 400 RNA Copies/ml but less than 5000 RNA Copies/ml, 4 (7,8%) 
had viral load that was above 5000 RNA Copies/ml and 1 (2,0%) patient did not respond. 
 
2.6.10 Correlation between Pill Count Method and Visual Analogue Scale (VAS) 
 
Figure 20.  Correlation between Pill Count Method and VAS 
 
 
 
2 Variables: PILL_COUNT_OVERALL VAS_ALL_DRUGS 
 
Simple Statistics 
Variable N Mean Std 
Dev 
Sum Minimum Maximum  
PILL_COUNT_OVERALL 50 97.56000 5.51865 4878 70.00000 100.00000  
VAS_ALL_DRUGS 51 97.64706 5.86114 4980 70.00000 100.00000  
 
 
 
Pearson Correlation Coefficients 
Probe > |r| under H0: Rho=0 
Number of Observations 
  PILL_COUNT_OVERALL VAS_ALL_DRUGS 
PILL_COUNT_OVERALL 
PILL_COUNT_OVERALL 
 
1.00000 
  
50 
0.83383 
<.0001 
50 
VAS_ALL_DRUGS 
VAS_ALL_DRUGS 
 
0.83383 
<.0001 
50 
1.00000 
  
51 
 
The correlation between pill count method and VAS is 0.83383 which is closer to 1. The two 
variables are positively related meaning they are almost giving the same results. The p-value 
(<.0001) shows that there is no significant difference between the two methods. The two 
measures are almost giving similar results. 
 
Figure 21.  Comparison between Pill Count and VAS Adherence 
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Overall all the patients had the same behaviour on the adherence for Pill Count Method as 
compared to Visual Analogue Scale.  
Forty two patients for both Pill Count and VAS had the adherence of more or equals to 95%, 
8 patients had adherence of less than 95% (Pill Count), 9 patients had adherence of less than 
95% (VAS) and 1 did not respond for Pill Count. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER 5 
 
5. LIMITATION AND RECCOMENDATION CONCLUSION 
 
5.1 LIMITATION OF THE STUDY 
The study used one group of participants in measuring if adherence counselling improves 
adherence to antiretroviral. The study should have given more effective results if two groups 
of the participants are used in the study with, the control group receiving no adherence 
counselling and the experimental group receiving adherence counselling. The reason why two 
groups are not used is that, it is unethical to put patient on antiretroviral without adherence 
counselling. The three sessions which our participants received prior adherence measure are 
the standard counselling that Pretoria West Hospital is using. 
 
5.2 RECOMMENDATION. 
o  Train health care professionals  more on HIV/AIDS and adherence counselling 
o In-depth training of counsellors on the basic knowledge of HIV/AIDS, drug literacy and 
adherence counselling 
o Use motivational strategies as part of adherence counselling. 
o Disseminate information to the patient on their progress or treatment outcomes. 
o The ongoing counselling especially by the pharmacist. 
o Encourage the involvement of all the multidisciplinary, in assisting the clients to adhere to 
antiretroviral 
o  Present and in-service to the staff on the development and new information as far as 
adherence is concerned. 
o Provide educational pamphlets on adherence and HIV/AIDS. 
o  Encourage the involvement of  the support partners as part of enhancing adherence 
o Empower the clients  who are on antiretroviral, through skills as, assertiveness and self help 
skills and e.t.c 
o Collaborate with the community based organization in promoting adherence to antiretroviral.  
o Encourage patient to join support groups, in order to encourage each other to adhere to 
antiretroviral. 
o Improve   adherence guidelines that are in use. 
o Provide government grants were appropriate to enhance adherence, to assist the clients to 
meet adherence requirements as dietary requirements. 
 
 
o Increase the number of counsellors, to attain quality of adherence service. 
o Involve the clients in planning for their service. 
o Measure adherence on a monthly basis, using at least two measures of adherence 
o Conduct more focus group discussion on adherence counselling to see the gaps and find 
priority for studies. 
o Monitor and evaluate the adherence counselling services. 
o Design and strengthen the patient follow-up system for defaulters and that patient who are not 
adhering to antiretroviral. 
o Most of all use this study as a guide to improve and design all activities of adherence.  
o Conduct case studies to know more on adherence behaviour. 
o Review salaries of counsellors to motivate and increase counsellor morale.  
o It is recommended that institution take adherence counselling as one of their highest 
priorities. 
o A good relationship between patient and staff is encouraged.  
 
5.3  CONCLUSION 
Adherence to antiretroviral improves the lives of those who are on antiretroviral. This goal 
will not be achieved if people are not adhering to antiretroviral. The health sectors report 
patient not adhering to antiretroviral or defaulting treatment. 
 
The study proves that adherence counselling improves adherence to antiretroviral. 
Assessment of the patient, information on HIV/AIDS, drug literacy, adherence strategies, 
assists the clients to adhere to antiretroviral. Clients adhere to antiretroviral when they know 
the consequences of non- adherence, as the risk of drug resistance. 
 
Assessment of the patient includes patient variables as the demographic data, and life style of 
the patient. The knowledge on the patient can help health care provider to know the kind of 
the regimen suitable for the patient. According to Sir Olser as cited in Fomundam (2008) it is 
very important to understand what kind of a person the patient is than to understand the kind 
of the disease the patient have. 
 
It is very important that adherence counsellors, which are all the trained health providers, 
provide adherence counselling   properly in order to enhance adherence to antiretroviral. If 
patient are not knowledgeable   on the information necessary to adhere are more likely to not 
 
 
adhere to treatment. Non – adherence undermine the efforts of the researchers in conducting 
studies on antiretroviral. 
 
The goal of adherence can be achieved with the health providers being equipped with the 
information on adherence. When staff members are equipped they are more confident in 
managing the patient on antiretroviral.  Adherence counselling need to be one of the priorities 
of institution. When adherence is prioritised people will leave longer on antiretroviral, thus 
reducing morbidity and mortality. 
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7. ANNEXURE 
 
 7.1 CONSENT FORM 
 
TOPIC: Proper Adherence Counselling Improves Adherence to Anti-retro viral. 
 
INVESTIGATOR: Chokoe Fridah Lesiba. 
The purpose of the study is to investigate if you are adhering to the Anti -retro viral. The 
study will benefit the patient /clients, as findings will help us improve adherence counselling 
that is currently in place and reduce burden associated with adherence   .The Hospital and the 
Department of Health will benefits. Knowledge of whether the clients are adhering or not, 
will help this institutions to design adherence guidelines ,which best enable the clients to 
adhere to Anti -retro viral, thus reducing the cost related to non –adherence .To my 
knowledge there is no risk associated with this study. 
 
Anonymity and confidentiality will be ensured .The presentation of findings will not include 
the identity of the participants. You have the right to refuse or agree to participate; in the 
study. Your participation in this study is voluntary. 
 
The study has been approved by Pretoria West Hospital, Department of Health and the 
University of Stellenbosch. 
 
I understand the above information and I voluntarily agree to participate in the study 
 
Signature of the participants...........................................              Date.............................. 
 
I have explained the study and content of the consent form to the participants  
 
Signature of the Investigator............................................             Date.............................. 
  
 
 
 
 
 
 
7.2 APPLICATION LETTER FOR THE PERMISSION TO CONDUCT THE STUDY                          
                                                                                 PRETORIA WEST HOSPITAL 
                                                                                PRETORIA 
                                                                               8/07/09 
 
 
                                                      
 
P.O. BOX 172 
HALFWAYHOUSE 
1685 
REQUEST FOR CONDUCTING THE STUDY 
I am hereby requesting to conduct the study at your Hospital. My topic is Proper Adherence 
Counselling improves adherence to Antiretrovirals. 
I am presently studying Masters in HIV/AIDS management at the University of Stellenbosch. 
I hope my request will be taken into consideration. 
Kind regards 
Chokoe F.L 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   DEMOGRAPHIC DATA 
 
     Age                 15-45  >45  
 
Gender  M F  
 
Marital Status Single Married Divorced Cohabiting Engaged 
 
Literacy Level Never attended school Primary Education Secondary 
Education 
Tertiary 
Education 
  
Employment Status Unemployed Pensioner Government Grant Employed Retrenched 
 
Residential Area Township Suburb Informal Settlement Other 
 
Disclosure Family  Friends Colleague 
 
Satisfaction with support from Health Professionals Family Friends Colleague 
 
Alcohol Consumption   Yes No Occasional  
 
Drug Use   Yes No  
 
Length of treatment in months      
 
Number of Pills  a day 1 2 3 4         5 6 7 8    
1 of 5
 
 
 
 
 
            PILL COUNT METHODS (This is done for all prescribed tablets) 
     
The formula is as follows: 
The Number of Tablets Dispensed -Tablet Returned   X 100 
 Number Prescribed 
E. g      60-4 x 100 
             56 
          =100 % 
1 ............... x..................... 
= 
2 ............... x..................... 
= 
3 ............... x..................... 
= 
Percentage ≥ 95 % indicate adherence, percentage below <95 indicate poor adherence and < 
70% adherence is unacceptable.   
LAST THREE DAYS RECALL METHODS 
In the last three days did you take all your tablets as prescribed?    Yes / No 
N.B Yes indicate 100% adherence and No indicate less than 100% adherence 
 
 
 
 
 
 MORISKY SCALE 
 
In answering the following information think of the medication prescribed by your doctor. 
 
 
2 of 5
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Response Options Never =0, Rarely=1 Sometimes=2, Often=3, Always=4. 
 0 
 
 
1 
 
 
2 3 4 
Do you ever forget to take your medications? 
 
     
Are sometimes careless about taking your medication?  
 
     
When you feel better, do you sometimes stop taking your  
Medications? 
 
     
Sometimes, if you feel worse when you take your medication, do you 
stop taking them? 
 
     
Adapted from National Resource Centre, 2008 
 
VISUAL ANALOGUE SCALE (VAS) 
 
The purpose of VAS is to assess your adherence level. I would like to know about your 
condition and how do you take your treatment. 
 
ARV’s requires to be taken at different times and has instructions on how to take them, for 
example with food or empty stomach. Patient on ARV’s at times end up forgetting to take 
their medications because of different reasons, as forgetfulness and side effects. 
 
Therefore the information needed from you is in regards to, how you take your pills the 
interest is on what is happening not what you think, I want to hear. You must not be afraid to 
mention, if you did not take your pill. 
 
Mark with an X  on the below 10cm line , a point which is your best guess as far as taking 
medication is concerned in the last four weeks. The drugs are listed from drug A to D. 
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0% means you have taken none of the drugs 
50% means you have taken half of the drugs 
100% means you have taken all the drugs  
Drug A 
1       2         3         4       5    6     7    8     9    1 0  
         
 
 
 
Drug B 
1       2         3         4       5    6     7    8     9    1 0  
         
 
Drug C 
1       2         3         4       5    6     7    8     9    1 0  
         
 
Drug D 
1       2         3         4       5    6     7    8     9    1 0  
         
 
 
CD4 COUNT RESULTS WILL BE ASSESED, COMPARED TO BASELINE, > 200 
CD4  count indicate improved immunity and  adherence  and < 200 CD4 count  indicate  a 
risk to opportunistic infections and poor adherence 
 
Baseline CD 4 Count................................        Recent CD 4 Count...................... 
 
VIRAL LOAD (VL) RESULTS WILL BE ASSESED, COMPARED TO BASELINE, < 
1000 VL indicate viral suppression  and adherence , and  > 1000 VL INDICATE poor 
suppression of VL   and poor adherence 
 
Baseline VL   .......................                               Recent VL................................. 
 
 
                                   
 
 
7.4 PILL COUNTS CHART 
 
NAME OF TABS               ADHERENCE PERCENTAGE 
STAVUDINE 
30MG    
60 TABS 
100% 
4T/R 
96% 
6T/R 
93% 
8T/R 
89% 
10T/R
86% 
12T/R
82% 
14T/R
80% 
16T/R
75% 
18T/R 
71% 
20T/R 
LESS 
THAN 
70% 
≥22T/R 
LAMIVUDINE 
150MG 
60 TABS 
100% 
4T/R 
96% 
6T/R 
93% 
8T/R 
89% 
10T/R
86% 
12T/R
82% 
14T/R
80% 
16T/R
75% 
18T/R 
71% 
20T/R 
LESS 
THAN 
70% 
≥22T/R 
EFIVARENZ 
200MG 
30TABS 
100% 
2T/R 
96% 
3T/R 
93% 
4T/R 
89% 
5T/R 
86% 
6T/R 
82% 
7 T/R 
80% 
8T/R 
75% 
9T/R 
71% 
10        
T/R 
LESS 
THAN 
70% 
≥11T/R 
NEVIRAPINE 
200MG 
TAB 
100% 
4T/R 
96% 
6T/R 
93% 
8T/R 
89% 
10T/R
86% 
12T/R
82% 
14T/R
80% 
16T/R
75% 
18T/R 
71% 
20T/R 
LESS 
THAN 
70% 
≥22T/R 
ZIDOVUDINE 
300MG 
TABS 
100% 
4T/R 
96% 
6T/R 
93% 
8T/R 
89% 
10T/R
86% 
12T/R
82% 
14T/R
80% 
16T/R
75% 
18T/R 
71% 
20T/R 
LESS 
THAN 
70% 
≥22T/R 
DIDANOSINE 
100MG 
TABS 
100% 
36T/R 
96% 
39T/R 
93% 
42T/R
89% 
45T/R
86% 
48T/R
82% 
51T/R
80% 
54T/R
75% 
57T/R 
71% 
60T/R 
LESS 
THAN 
70% 
≥63T/R 
DIDANOSINE 
100MG 
TABS 
100% 
8T/R 
96% 
12T/R 
93% 
16T/R
89% 
20T/R
86% 
24T/R
82% 
28T/R
80% 
32T/R
75% 
36T/R 
71% 
40T/R 
LESS 
THAN 
70% 
 
 
≥44T/R 
KALETRA 
133/33MG 
TABS 
100% 
12T/R 
96% 
18T/R 
93% 
24T/R
89% 
30T/R
86% 
36T/R
82% 
48T/R
80% 
54T/R
75% 
60T/R 
71% 
66T/R 
LESS 
THAN 
70% 
≥63T/R 
 
